Untersuchungen zur Rolle der onkogenen und wildtypischen B-RAF Kinase in Lungentumormodellen der Maus by Zanucco, Emanuele
  
Role of oncogenic and wild type B-RAF in 
mouse lung tumor models 
 
Untersuchungen zur Rolle der onkogenen 
und wildtypischen B-RAF Kinase in 
Lungentumormodellen der Maus 
 
Doctoral thesis for a doctoral degree 
at the Graduate School of Life Sciences, 
Julius-Maximilians-Universität Würzburg, 
Section Infection and Immunity 
 
 
Submitted by 
Emanuele Zanucco 
from  
San Vito di Cadore (Italy) 
 
Würzburg 2011 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Submitted on: …………………………………………………………..………………… 
                                                     Office stamp 
 
Members of the Promotionskomitee: 
Chairperson: Prof. Thomas Dandekar  
Primary Supervisor: Prof. Ulf R. Rapp 
Supervisor (Second): Dr. PD Rudolf Götz 
Supervisor (Third):  Prof. Ricardo Benavente 
Supervisor (Fourth): Prof. Roland Benz  
Date of Public Defence: …………………………………………………………..……… 
Date of receipt of Certificates: ………………………………………………………….  
 
 
Table of contents 
 
1 
 
Table of contents 
SUMMARY ........................................................................................................................................................4 
ZUSAMMENFASSUNG .......................................................................................................................................6 
1. INTRODUCTION .......................................................................................................................................8 
1.1 LUNG............................................................................................................................................................... 8 
1.1.1 Lung development ................................................................................................................................. 8 
1.1.2 Lung defense mechanisms .................................................................................................................. 10 
1.2 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) .......................................................................................... 12 
1.2.1 Histopathology of COPD ...................................................................................................................... 12 
1.2.2 COPD and lung cancer ......................................................................................................................... 12 
1.3 LUNG CANCER ................................................................................................................................................. 14 
1.3.1 Histopathology of lung cancer ............................................................................................................ 14 
1.3.2 Genetic of lung cancer......................................................................................................................... 14 
1.4 DEVELOPMENTAL SYNDROMES OF CANCER RELATED GENES ...................................................................................... 16 
1.5 THE MAPK CASCADE ........................................................................................................................................ 17 
1.5.1 Ras/RAF-signalling .............................................................................................................................. 17 
1.5.2 RAF isoforms ....................................................................................................................................... 19 
1.5.3 RAF and cancer.................................................................................................................................... 20 
1.5.4 RAFs driven mouse lung tumor models ............................................................................................... 22 
1.6 EXPERIMENTAL DESIGN AND AIM OF THE PROJECT ................................................................................................... 24 
1.6.1 Lung-targeted expression of oncogenic B-RAF V600E......................................................................... 24 
1.6.2 Elimination of B-RAF in a mouse model for NSCLC .............................................................................. 25 
2. RESULTS (LUNG-TARGETED EXPRESSION OF ONCOGENIC B-RAF V600E) ................................................ 28 
2.1 GENERATION OF TRANSGENIC MICE WITH LUNG-TARGETED EXPRESSION OF B-RAF V600E ........................................... 28 
2.1.1 Construction of SpC-B-RAF V600E plasmid ........................................................................................ 28 
2.1.2 Generation of SpC-B-RAF V600E transgenic mice .............................................................................. 29 
2.2 CHARACTERIZATION OF SPC-B-RAF V600E TRANSGENIC MICE ................................................................................ 31 
2.2.1 Expression of B-RAF V600E in alveolar type II cells leads to airway enlargements in mice ................ 31 
2.2.2 Increased apoptosis and absence of MAPK signaling activation ........................................................ 35 
2.2.3 Signs of tissue remodeling................................................................................................................... 38 
2.2.4 Induction of inflammation .................................................................................................................. 43 
2.2.5 Synergistic effect of oncogenic B- and C-RAF in SpC-B-RAF V600E/SpC-C-RAF BxB 23 compound 
mice 48 
2.2.6 Delayed tumor formation in SpC-B-RAF V600E transgenic ................................................................. 51 
2.2.7 T- and B-lymphocytes are not involved in the development of COPD-like lesion and lung tumor ...... 54 
Table of contents 
 
2 
 
3. DISCUSSION (LUNG-TARGETED EXPRESSION OF ONCOGENIC B-RAF V600E) .......................................... 56 
4. RESULTS AND DISCUSSION (ELIMINATION OF B-RAF IN A MOUSE MODEL FOR NSCLC) ......................... 61 
4.1 RATIONALE .................................................................................................................................................... 61 
4.2 ONCOGENIC C-RAF COOPERATES WITH B-RAF IN LUNG TUMOR GROWTH .................................................................. 62 
4.3 REDUCED CELL PROLIFERATION IN LUNG TUMORS LACKING B-RAF ............................................................................. 65 
4.4 B-RAF COOPERATES WITH ONCOGENIC C-RAF IN THE ACTIVATION OF THE MAPK CASCADE .......................................... 67 
5. MATERIALS AND METHODS ........................................................................................................................ 71 
5.1 MATERIALS ..................................................................................................................................................... 71 
5.1.1 Instruments ......................................................................................................................................... 71 
5.1.2 Disposable materials ........................................................................................................................... 72 
5.1.3 Chemicals ............................................................................................................................................ 72 
5.1.4 Antibodies ........................................................................................................................................... 75 
5.1.4.1 Primary antibodies ........................................................................................................................................ 75 
5.1.4.2 Secondary antibodies .................................................................................................................................... 76 
5.1.5 Plasmids .............................................................................................................................................. 76 
5.1.6 Oligonucleotides .................................................................................................................................. 76 
5.1.7 Enzymes .............................................................................................................................................. 80 
5.1.8 Kits....................................................................................................................................................... 80 
5.1.9 Bacterial strains and Mouse lines ....................................................................................................... 81 
5.2 METHODS ...................................................................................................................................................... 82 
5.2.1 Bacterial manipulation ........................................................................................................................ 82 
5.2.1.1 Transformation of competent bacteria ......................................................................................................... 82 
5.2.1.2 Purification of plasmid DNA .......................................................................................................................... 82 
5.2.2 DNA analysis ....................................................................................................................................... 83 
5.2.2.1 Measurement of DNA concentration ............................................................................................................ 83 
5.2.2.2 Enzymatic digestion of DNA with restriction enzymes .................................................................................. 83 
5.2.2.3 Ligation of DNA fragments ............................................................................................................................ 83 
5.2.2.4 Polymerase-Chain-Reaction (PCR) ................................................................................................................. 84 
5.2.2.5 Agarose gel electrophoresis .......................................................................................................................... 85 
5.2.2.6 DNA fragment extraction from agarose gel .................................................................................................. 85 
5.2.2.7 DNA sequencing ............................................................................................................................................ 85 
5.2.3 RNA analysis ........................................................................................................................................ 86 
5.2.3.1 RNA isolation from cells and tissues ............................................................................................................. 86 
5.2.3.2 Measurement of RNA concentration ............................................................................................................ 86 
5.2.3.3 cDNA synthesis .............................................................................................................................................. 86 
5.2.3.4 Real-Time PCR ............................................................................................................................................... 87 
5.2.4 Protein analysis ................................................................................................................................................ 88 
5.2.4.1 Preparation of whole protein lysates from cells and tissues ......................................................................... 88 
Table of contents 
 
3 
 
5.2.4.2 Measurement of protein concentration ....................................................................................................... 88 
5.2.4.3 SDS-PAGE ...................................................................................................................................................... 89 
5.2.4.4 Immunoblotting ............................................................................................................................................ 90 
5.2.4.5 Stripping of membrane ................................................................................................................................. 92 
5.2.5 Mouse work......................................................................................................................................... 92 
5.2.5.1 Generation of transgenic mice ...................................................................................................................... 92 
5.2.5.2 Breeding of mice ........................................................................................................................................... 93 
5.2.5.3 Genotyping of mice ....................................................................................................................................... 93 
5.2.5.4 Sacrification of mice ...................................................................................................................................... 94 
5.2.5.5 Lung type II cells isolation ............................................................................................................................. 94 
5.2.6 Histological techniques ....................................................................................................................... 95 
5.2.6.1 Paraffin-embedding and sectioning of tissue ................................................................................................ 95 
5.2.6.2 Optimal Cutting Temperature (O.C.T.)-embedding and cryosectioning of tissue ......................................... 97 
5.2.6.3 Hematoxilin and Eosin staining of tissue (H & E staining) ............................................................................. 98 
5.2.6.4 Immunostaining of tissue .............................................................................................................................. 98 
5.2.6.5 Immunohistopathological analysis of tissue ............................................................................................... 101 
5.2.6.6 PCR-amplification of genomic DNA from paraffin section .......................................................................... 103 
5.2.7 Statistical analysis ............................................................................................................................. 103 
8. REFERENCES ......................................................................................................................................... 104 
7. APPENDIX ................................................................................................................................................. 112 
7.1 ABBREVIATIONS ............................................................................................................................................. 112 
8. ACKNOWLEDGMENTS ............................................................................................................................... 115 
9. CURRICULUM VITAE .................................................................................................................................. 117 
10. AFFIDAVIT ............................................................................................................................................... 120 
  
Summary 
 
4 
 
Summary 
Growth factor induced signaling cascades are key regulatory elements in tissue 
development, maintenance and regeneration. Deregulation of the cascades has 
severe consequences, leading to developmental disorders and neoplastic 
diseases. As a major function in signal transduction, activating mutations in RAF 
family kinases are the cause of many human cancers. 
In the first project described in this thesis we focused on B-RAF V600E that has 
been identified as the most prevalent B-RAF mutant in human cancer. In order to 
address the oncogenic function of B-RAF V600E, we have generated transgenic 
mice expressing the activated oncogene specifically in lung alveolar epithelial 
type II cells. Constitutive expression of B-RAF V600E caused abnormalities in 
alveolar epithelium formation that led to airspace enlargements. These lung 
lesions showed signs of tissue remodeling and were often associated with 
chronic inflammation and low incidence of lung tumors. Inflammatory cell 
infiltration did not precede the formation of emphysema-like lesions but was 
rather accompanied with late tumor development. These data support a model 
where the continuous regenerative process initiated by oncogenic B-RAF-driven 
alveolar disruption provides a tumor-promoting environment associated with 
chronic inflammation. 
In the second project we focused on wild type B-RAF and its role in an 
oncogenic-C-RAF driven mouse lung tumor model. Toward this aim we have 
generated compound mice in which we could conditionally deplete B-RAF in 
oncogenic-C-RAF driven lung tumors. Conditional elimination of B-RAF did not 
block lung tumor formation however led to reduced tumor growth. The diminished 
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tumor growth was not caused by increased cell death instead was a 
consequence of reduced cell proliferation. Moreover, B-RAF ablation caused a 
reduction in the amplitude of the mitogenic signalling cascade. These data 
indicate that in vivo B-RAF is dispensable for the oncogenic potential of active C-
RAF; however it cooperates with oncogenic C-RAF in the activation of the 
mitogenic cascade.           
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Zusammenfassung 
Von Wachstumsfaktoren regulierte Signalkaskaden sind Schlüsselelemente in 
der Gewebeentwicklung und Geweberegeneration. Eine Deregulation dieser 
Kaskaden führt zu Entwicklungsstörungen und neoplastischen Krankheiten. Für 
viele humane Krebsformen sind aktivierende Mutationen der Kinasen der RAF 
Familie verantwortlich. 
Das erste Projekt dieser Doktorarbeit fokussiert auf der Rolle des B-RAF V600E, 
welches als eine der am häufigsten vorkommenden Mutantionen in humanen 
Krebszellen identifiziert worden ist. Um die onkogene Funktion des B-RAF V600E 
zu untersuchen, haben wir transgene Mauslinien hergestellt, welche das 
aktivierte Onkogen spezifisch in alveolaren Lungenepithelzellen des Typ II 
exprimieren. Konstitutive Expression des B-RAF V600E führte zu einer abnormen 
alveolaren Epithelzellbildung und zu Emphysem-ähnlichen Läsionen. Diese 
Läsionen wiesen Zeichen einer Gewebsumstrukturierung auf, oft in Assoziation 
mit chronischer Inflammation und geringer Inzidenz von Lungentumoren. Die 
Infiltration der entzündlichen Zellen erfolgte erst nach der Entstehung von 
Emphysem-ähnlichen Läsionen und könnte zur späteren Tumorbildung 
beigetragen haben. Diese Ergebnisse unterstützen ein Modell,  in welchem der 
kontinuierliche regenerative Prozess eine tumorfördernde Umgebung schafft.  
Dabei induziert die Aktivität des onkogenen B-RAF eine alveolare Störung, 
welche ursächlich verantwortlich ist für den kontinuierlichen regenerativen 
Prozess. 
Das zweite Projekt fokussiert auf die Rolle von endogenem (wildtypischen) B-
RAF in einem durch onkogenes C-RAF induzierten Maus Lungentumormodell. 
Zusammenfassung 
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Für unsere Untersuchungen haben wir eine Mauslinie geschaffen, in welcher B-
RAF in den C-RAF Lungentumoren konditionell eliminiert werden kann. Eine 
konditionelle Eliminierung des B-RAF hat die Entstehung von Lungentumoren 
nicht blockiert, aber zu reduziertem Tumorwachstum geführt. Dieses reduzierte 
Tumorwachstum konnte auf eine reduzierte Zellproliferation zurückgeführt 
werden. Außerdem konnten wir durch die B-RAF Elimination eine Reduktion der 
Intensität der mitogenen Signalkaskade beobachten. Insgesamt deuten die 
Ergebnisse darauf hin, dass das onkogene Potential von C-RAF in vivo 
unabhängig von B-RAF ist und eine Kooperation von B-RAF und C-RAF jedoch 
für die vollständige Aktivierung der mitogenen Signalkaskade wichtig ist. 
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1. Introduction 
1.1 Lung  
1.1.1 Lung development  
Mammalian lungs are branched networks containing thousands to millions of 
airways arrayed in intricate patterns that are crucial for respiration (Metzger, Klein 
et al. 2008). Lung development is divided into five distinct phases that are 
generally shared, but vary temporally and regionally among diverse vertebrate 
species (Maeda, Dave et al. 2007). In the mouse, lung organogenesis starts at 
embryonic day 9,5 (E9,5) and ends in postnatal age (PN) at about 21 days 
(PN21) (figure 1.1) (Greenlee, Werb et al. 2007) (Maeda, Dave et al. 2007).  
 
Figure 1.1 Mouse lung development. Five distinct stages of lung development: Primary 
Budding (E 9.5-11.5), Pseudoglandular ( E 12.5-16.5), Canalicular (E 17-18), Saccular 
(E 19-P5) and Alveolar (P 5-21); E= embryonic, P= Postnatal (Greenlee, Werb et al. 
2007).      
 
In the primary budding phase, two lung buds appear on the ventral-lateral aspect 
of the foregut and evaginate into the splanchnic mesenchyme as the primordial 
trachea and the two main bronchi are formed. Moreover, the tracheal and 
bronchial salks extend to form the main bronchi (Maeda, Dave et al. 2007). In the 
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pseudoglandular phase the preacinar branching pattern of airways and blood 
vessels is established (Jeffrey 1998). Many transcription factors are required for 
the development of the early foregut and are also later utilized in lung 
morphogenesis and maintenance. Among these, for example, deletion of Nkx2.1, 
Foxa2, Catnb, Sox17, Gata-6 and Stat3 genes leads to failure of normal 
embryonic patterning even before lung formation (Ang and Rossant 1994) 
(Huelsken, Vogel et al. 2000) (Kanai-Azuma, Kanai et al. 2002) (Morrisey, Tang 
et al. 1998) (Takeda, Noguchi et al. 1997). Before E15, lung cells are relatively 
undifferentiated as defined by cell-specific markers used to identify epithelial cell 
types. During canalicular period the airways epithelium goes into differentiation, 
later on in saccular and alveolar phases, which mainly take place during 
postnatal maturation, septae are forming in the terminal sacs leading to the 
expansion of the gas-exchange surface (Cardoso and Lu 2006). The adult lung is 
a very complex organ that includes over 40 different cell types. The most studied 
pulmonary epithelial cells include Clara cells and Bronchio-Alveolar Stem Cells 
(BASCs) which are localized in trachea, bronchi and bronchioli, and Type I and 
Type II cells which are situated in the alveoli (Cardoso and Lu 2006). Type II cells 
secrete surfactant proteins such as SP-C which have a pivotal role in maintaining 
lung integrity and function. Moreover, Type II cells are the precursor of Type I 
pneumocytes which are the cells lining the alveoli (Cardoso and Lu 2006). The 
SP-C protein is not only expressed in alveolar Type II cells but also in a rare 
population of cells which are localized at the bronchio-alveolar duct-junction that 
also express the Clara cell-specific protein (CC10). It has been initially proposed 
that these cells are Bronchio-Alveolar Stem Cells (BASCs) that give rise to both 
bronchiolar and alveolar cells in vivo (Kim, Jackson et al. 2005). However, more 
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recent work using lineage-tracing strategy did not support the model in which 
BASCs function as stem cells to maintain the postnatal bronchioles. Furthermore, 
BASCs do not contribute significantly to the alveoli (Rawlins, Okubo et al. 2009). 
1.1.2 Lung defense mechanisms 
Pulmonary defense involves a wide and complex range of mechanisms that are 
necessary to remove inhaled particles and microorganisms. The first protection of 
the upper airways and bronchi is the nasopharyngeal anatomic barrier which 
efficiently prevents the penetration of particles or microorganisms bigger then 2–3 
µm into the lower airways (Nicod 1999). The vast majority of particles bigger then 
2–3 µm is collected on the mucus overlaying the ciliated epithelium (Nicod 1999). 
Many important elements contributing to lung defense for their bactericidal 
properties are included in the mucus. Among them are the secretory IgA, 
lysozyme, lactoferrin or peroxydases (Puchelle 1992). The mucociliary clearance 
is altered in many lung diseases such as asthma, chronic bronchitis or cystic 
fibrosis. Airway epithelial cells also actively participate in host defense 
mechanisms by secreting surfactant proteins, which play a pivotal role in innate 
and adaptive immunity (Wright and Churg 2006). SP-C for example has a major 
role in leukocyte trafficking and lung remodeling. Moreover, airway epithelial cells 
recruit immune cells by secreting various chemokines and cytokines such as GM-
CSF, IL1ß, IL8, TNFα and IFNγ (Nicod 1999).  In the absence of inflammation the 
lung epithelium includes a small fraction (~ 1%) of CD4 and CD8 T-lymphocytes. 
These cells are likely to play an important role in lung immunity where they react 
to pathogens in the absence of preliminary priming (Nicod 1999). Bronchus-
associated lymphoid tissues (BALT), which are agglomerates of T- and B-
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lymphocytes, were originally described as submucosal lymphoid organs, found 
along the bifurcations of the upper bronchi directly beneath the epithelium 
(Sminia, van der Brugge-Gamelkoorn et al. 1989). Although some species 
appear to develop BALT independent from antigenic stimulation (Pabst and 
Gehrke 1990), most normal mice and humans have little evidence of BALT 
(Tschernig and Pabst 2000). However, lung infection or inflammation in mice 
leads to the development of lymphoid follicles that are not restricted to the upper 
airways and are termed inducible BALT (iBALT) (Moyron-Quiroz, Rangel-Moreno 
et al. 2004). Also pulmonary macrophages have a key role in defense against 
respiratory infection and are very important in both innate and acquired immunity 
(Gordon and Read 2002). Due to their position in the alveolar lumen, resident 
alveolar macrophages are continuously entering in contact with inhaled 
substances (Lambrecht 2006). In order to avoid collateral damage to pulmonary 
cells in response to harmless antigens, macrophages are normally kept in a 
quiescent state by closely adhering to alveolar epithelial cells and by producing 
little inflammatory cytokines (Lambrecht 2006). Alveolar macrophages play a 
critical role in the pathophysiology of inflammatory lung diseases such as Chronic 
Pulmonary Disease (COPD) (Barnes 2004). Macrophage numbers are markedly 
increased in the airway spaces of patients with COPD and are localized at the 
sites of alveolar destruction (Barnes 2004). Moreover, alveolar macrophages of 
patients with COPD display and increased baseline and stimulated secretion of 
inflammatory proteins, including certain cytokines, chemokines and reactive 
oxygen species (Barnes 2004).  
   
Introduction 
 
12 
 
1.2 Chronic Obstructive Pulmonary Disease (COPD) 
1.2.1 Histopathology of COPD 
COPD is a group of lung diseases that cause obstruction of the airways. This 
results in a reduction of airflow both into, and out, of the lungs. COPD 
encompasses two groups of lung diseases: emphysema and chronic bronchitis. 
Emphysema is defined as an abnormal, permanent enlargement of the airspaces 
distal to the terminal bronchiole accompanied by destruction of their walls´ and 
´without obvious fibrosis´ (Wright and Churg 2006). Chronic bronchitis is 
characterized by inflammation of the bronchi which is accompanied by alteration 
of the epithelium with goblet cell hyperplasia and metaplasia coupled with an 
increase in fibrotic tissue and smooth muscles (Wright and Churg 2006).   
According to the World Health Organization, COPD is the fourth leading cause of 
death in the world, with approximately 2.75 million deaths each year (Raherison 
and Girodet 2009). The projection for 2020 indicates that COPD will be the third 
leading cause of death worldwide (Raherison and Girodet 2009). There are 
currently no cures for COPD and no ways to reverse the damage to the airways 
and lungs that has already occurred.  
1.2.2 COPD and lung cancer 
In the mid-1980s, two groups independently demonstrated that lung cancer 
incidence increased in individuals with COPD (Tockman, Anthonisen et al. 1987) 
(Skillrud, Offord et al. 1986). However, it is difficult to imagine common molecular 
mechanisms between two diseases that seem to be diametrically opposed. 
COPD is specified by inflammation-mediated destruction of the extracellular 
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matrix, whereas lung cancer is characterized by an uncontrolled cell proliferation 
(Houghton, Mouded et al. 2008). In the past decades, very little has been done to 
explore the link between these two diseases. Nevertheless, by use of computer 
tomography chest imaging researchers could show that just the presence of 
emphysema predisposes an individual to lung cancer (de Torres, Bastarrika et al. 
2007) (Wilson, Weissfeld et al. 2008). These important clinical findings will 
require new mechanistic hypothesis and molecular models to understand the 
connections between these related pathologies (Houghton, Mouded et al. 2008).  
One hypothesis considers that the inflammation and the body´s attempt to repair 
emphysematous airspaces might link these diseases. Emphysema starts when 
inhaled particles, contained in cigarette smoke, induce a mild lung inflammation 
associated with matrix-degrading proteinases such as elstases (Shapiro 2005). 
Cell death is the first consequence of the tissue destruction caused by these 
proteinases (Shapiro 2005). Moreover, inflammatory cells like macrophages and 
neutrophils can at this site secrete pro-tumorigenic factors (Coussens, Tinkle et 
al. 2000). In the same time, it is likely that progenitor cells are under constant 
pressure to proliferate and repair the chronic damaged areas of the lung 
(Houghton, Mouded et al. 2008). However, it could be that in this carcinogen-rich, 
inflammatory milieu, one of these progenitor cells start to proliferate in an 
uncontrolled manner and then give rise to lung cancer (Houghton, Mouded et al. 
2008). In line with this hypothesis, it has been shown that in COPD patients the 
corticosteroids-mediated inhibition of inflammation reduced the lung cancer 
incidence (Houghton, Mouded et al. 2008).      
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1.3 Lung cancer 
1.3.1 Histopathology of lung cancer 
Lung cancer is the first cause of cancer related death worldwide. During the past 
20 years many efforts have been made to reduce the mortality of lung cancer 
patients (Carney 2002). Traditional treatments comprise surgery, radiotherapy, 
chemotherapy or most often a combination of those. Recently, small molecule 
inhibitors and monoclonal antibodies have been developed to specifically target 
key molecules in cancer initiation and progression. However, despite all 
improvements, patients are usually diagnosed at late stages and therefore the 
five-year survival rate is less than 15% (Carney 2002).  
Based on size and morphology of the cells, lung cancer has been divided into two 
major categories: Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung 
Cancer (NSCLC). SCLC accounts for ~20% of lung cancer and arises from 
neuroendocrine cells. NSCLC, which account for ~80% of lung cancer, originates 
from epithelial cells and it is divided into four subcategories: Squamous cell 
carcinoma, Adenocarcinoma, Bronchioalveolar carcinoma and Large-cell 
undifferentiated carcinoma (Brambilla, Travis et al. 2001). Adenocarcinoma, 
which account for 30-40% of NSCLC, is the most common type of lung cancer 
(Brambilla, Travis et al. 2001).    
1.3.2 Genetic of lung cancer 
Molecular genetic studies have demonstrated that lung cancer tissues display 
multiple genetic and epigenetic abnormalities, including DNA sequence 
alterations, copy number changes, and aberrant promoter hypermethylation 
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(Sato, Shames et al. 2007). The most frequent aberrations found in human 
NSCLC and SCLC are reported in the Table 1.1 [modified from (Meuwissen and 
Berns 2005)].  
 
Gene  Aberration NSCLC frequency SCLC frequency 
MYC Amplification 5%-20% 20%-35% 
RAS Mutations 15%-20% <1% 
EGFR Mutations 20% - 
INK4a LOH 70% 50% 
p16INK4a Mutations 20%-50% <5% 
p14ARF Mutations 20% 65% 
TP53 LOH 60% 75%-100% 
TP53 Mutations 50% 75% 
RB LOH 30% 70% 
RB Mutations 15%-30% 90% 
FHIT Mutations 40% 80% 
TSG101 Mutations - 90% 
DMBT1 Mutations 40%-50% 100% 
LOH in various regions 
(3p, 4p, 4q, 8p) 
LOH 10%-100% 50-100% 
INK4a Promoter Hm. 8%-40% ND 
RARβ Promoter Hm. 40% 70% 
RASSF1A Promoter Hm. 30%-40% 90%-100% 
CDH1 Promoter Hm. 55% ND 
 
Table 1.1. Major genetic aberrations in human NSCLC and SCLC (LOH indicates 
loss of heterozygosity, Hm.= hypermethylation, ND= not determined).  
 
Notably, the Ras-mitogen-activated protein kinase (MAPK) pathway is 
deregulated in 50% of human lung cancer and the Ras GTPase is one of the 
most frequently mutated gene in NSCLC (Forbes, Bindal et al. 2011) (Ding, Getz 
et al. 2008).  
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1.4 Developmental syndromes of cancer related genes 
RAS genes are well-studied cancer-related genes due to their frequent activation 
in human cancers and play a central role in the MAPK signaling cascade, which 
has a pivotal role in cell proliferation, differentiation, survival, and cell death 
(Barbacid 1987) (Malumbres and Barbacid 2003) (Giehl 2005). Studies on RAS 
and its downstream targets have been mainly focused on their role in tumor 
development although the function of the wild type form of these genes in 
humans has not been well elucidated. Recently, germline mutations in H-RAS 
and K-RAS and in genes encoding other molecules in the Ras–RAF–MEK–ERK 
cascade were shown to underlie cases of Noonan, Costello syndromes and 
Cardio-facio-cutaneous syndrome (CFC) (Table 1.2) (Schubbert, Bollag et al. 
2007) (Tidyman and Rauen 2009).  
 
Syndrome MAPK pathway gene Protein 
Noonan PTPN11 
SOS1 
RAF1 
KRAS 
SHP2 
SOS1 
C-RAF 
KRAS 
Leopard PTPN11 
RAF1 
SHP2 
C-RAF 
Costello HRAS HRAS 
CFC B-RAF 
MAP2K1 
MAP2K2 
KRAS 
B-RAF 
MEK1 
MEK2 
KRAS 
 
Table 1.2. Genetic syndromes of the Ras/MAPK pathway [modified from (Tidyman 
and Rauen 2009)].  
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These syndromes are autosomal dominant multiple congenital anomaly 
syndromes characterized by a distinctive facial appearance, heart defects, 
musculocutaneous abnormalities, and mental retardation (Schubbert, Shannon et 
al. 2007). Notably, although many of the mutated genes encode for proteins with 
an increased kinase activity, malignant tumors are relatively uncommon in 
patients affected by these disorders (Schubbert, Shannon et al. 2007).   
 
1.5 The MAPK cascade 
1.5.1 Ras/RAF-signalling 
The MAPK pathway is a key signalling pathway that is involved in the regulation 
of normal cell proliferation, survival, growth, differentiation, and apoptosis 
(Roberts and Der 2007) (Robinson and Cobb 1997) (Wellbrock, Karasarides et 
al. 2004). Mutations or over expression of the components of this signalling 
network are hallmark of several human cancers and other human diseases 
(Roberts and Der 2007).  
As described in the figure 1.2 (Rapp, Fensterle et al. 2003), the binding of growth 
factors and/or hormones to cell-surface receptor tyrosine kinases and G-protein-
coupled receptors, respectively, leads to Ras activation (McCubrey, Steelman et 
al. 2007). This initiates membrane recruitment and activation of RAF, which leads 
to the activation of the dual-specificity mitogen-activated protein kinase (MAPK) 
and extracellular signal-regulated kinase (ERK) kinases (MEK) 1 and/or MEK2 
and, subsequently, ERK1 and/or ERK2 (Wellbrock, Karasarides et al. 2004). The 
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ERKs have many cytosolic and nuclear substrates (Wellbrock, Karasarides et al. 
2004). 
 
 
Figure 1.2. Overview of the Ras/MAPK pathway (Rapp, Fensterle et al. 2003).  
 
Although the Ras/MAPK pathway is traditionally drawn as a linear, unidirectional 
cascade of protein kinases, the more appropriate depiction of this cascade is that 
it is a key core element of a complex signalling network, with many other 
interactions (Kolch 2005). RAF proteins have, indeed, different MEK/ERK 
independent functions. RAFs have been shown to inhibit apoptosis by interacting 
with proteins localized at mitochondria such as Bcl-2 and BAD (Wang, Rapp et al. 
1996) (Panka, Wang et al. 2006) (Kebache, Ash et al. 2007) (Polzien, Baljuls et 
al. 2009) (Polzien, Baljuls et al.). Moreover, RAFs stimulate survival programs by 
activating the NFkB pathway through interaction with the membrane shuttle 
kinase MEKK1 (Li and Sedivy 1993) (Baumann, Weber et al. 2000). 
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1.5.2 RAF isoforms 
Lower organisms, like Drosophila melanogaster or Caenorhabditis elegans have 
only one RAF gene, mammals have instead three functional RAF genes (A-, B- 
and C-RAF) (Galabova-Kovacs, Kolbus et al. 2006). B-RAF is the most similar to 
the RAFs of lower organisms (Galabova-Kovacs, Kolbus et al. 2006). Although 
they differ in size and for basal enzymatic activity all RAFs contain three highly 
conserved regions (figure 1.3) (Wellbrock, Karasarides et al. 2004) (Baljuls, 
Schmitz et al. 2008). The first two (CR1 and CR2) conserved regions are 
localized in the N terminus, the third (CR3) in the C terminus where also the 
kinase domain is localized (Wellbrock, Karasarides et al. 2004). 
 
 
Figure 1.3. Schematic representation of human RAF kinases [modified from (Baljuls, 
Schmitz et al. 2008)]. A-, B- and C-RAF share three highly conserved domains (blue). In 
the CR1 region are situated the Ras binding domain (red) and the cysteine-rich domain 
(yellow) which are necessary for membrane recruitment. The CR2 domain is another 
important regulatory domain which contains a 14-3-3 binding site. The CR3 domain 
contains the catalytic domain that includes the MEK binding site (light blue) and the 
activation segment (pink) (Baljuls, Schmitz et al. 2008). 
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Genetic studies of mice with inactivated Raf genes have shown that Raf proteins 
signal non-redundant functions during development (Pritchard, Bolin et al. 1996) 
(Wojnowski, Zimmer et al. 1997) (Wojnowski, Stancato et al. 1998) (Mikula, 
Schreiber et al. 2001). A-raf -/- mice survive to birth but they die after 7-21 days 
due to gastrointestinal and neurological defects (Pritchard, Bolin et al. 1996). B-
raf -/- and c-raf -/- embryos die between day 10.5 and 12.5 days post-coitum. B-
raf -/- embryos show vascular defects with endothelial cell death and growth 
retardation (Wojnowski, Zimmer et al. 1997). C-raf -/- embryos are growth 
retarded and die at midgestation with anomalies in the placenta and in the fetal 
liver caused by massive apoptosis of hepatocytes (Mikula, Schreiber et al. 2001). 
The activity of RAF protein kinases is tightly regulated by multiple 
phosphorylation events to direct ERK MAPK signalling to distinct subcellular 
compartments in response to growth factor stimulation (Nekhoroshkova, Albert et 
al. 2009). The formation of RAFs homo- and heterodimers, that is necessary for 
kinase activity, is mainly mediated by scaffold proteins such as 14-3-3 and 
Kinase-Suppressor-of-Ras (KSR) (Roskoski 2010). 
1.5.3 RAF and cancer 
The first Raf gene was described as retroviral oncogene, v-raf, transduced by a 
murine sarcoma virus (Rapp, Goldsborough et al. 1983). This transforming 
retrovirus encoded the first oncogene with serine/threonine kinase activity 
(Moelling, Heimann et al. 1984).   After the cellular proto-oncogene homologs, C-
raf and the other RAF isoforms, had been cloned, the majority of the studies 
focused on elucidating the function of RAF proteins. For almost two decades 
research concentrated on RAF proteins as the critical effector of Ras (Matallanas, 
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Birtwistle et al. 2011). Recently, this changed when B-RAF mutations were found 
in several human cancers, particularly melanoma (30–60%), thyroid cancer (30–
50%), colorectal cancer (5–20%) and ovarian cancer ( 30%), but also at a low 
frequency (1–3%) in a number of other cancers (Davies, Bignell et al. 2002).  
 
Figure 1.4. Schematic representation of the human B-RAF kinase with its 
mutations [modified from (Wellbrock, Karasarides et al. 2004)]. The majority of B-RAF 
mutations are localized in the kinase domain (C3). In the C3 domain there are two main 
clusters of mutations: one in the Glycine-rich loop, the other in the Activation-segment 
where the V600 aminoacid is situated. The V600 is the most frequently mutated B-RAF 
site.  
 
The majority of mutations are single non-sense substitutions that render the 
kinase constitutively active (Davies, Bignell et al. 2002). ~90% of all B-RAF 
mutations consist of a single substitution of a valine residue at position 600 for 
glutamic acid (figure 1.4) (Davies, Bignell et al. 2002) (Wellbrock, Karasarides et 
al. 2004). The B-RAF V600E mutant, which is the most important human RAF 
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oncogene, display a 700 fold increased kinase activity compared to the wild type 
B-RAF (Wan, Garnett et al. 2004). In regard to the other RAFs, detailed analysis 
of the mutational status of A-RAF and C-RAF in several cancer cell lines and 
primary human samples showed that mutations in these RAF genes are very rare 
or nonexistent events (Fransen, Klintenas et al. 2004) (Lee, Soung et al. 2005) 
(Emuss, Garnett et al. 2005). 
Although point mutations are the most common, RAF genes can be mutationally 
activated by chromosome translocations, as observed in thyroid cancer and 
pilocytic astrocytoma (Ciampi, Knauf et al. 2005) (Jones, Kocialkowski et al. 
2008) (Jones, Kocialkowski et al. 2009). More recently, Palanisamy et al. 
identified chromosomal translocations involving either B- or C-RAF in a small 
percentage of prostate and gastric cancers and melanoma (Palanisamy, Ateeq et 
al. 2010) (McMahon 2010). Notably, these gene fusions encode for RAF proteins 
retaining the kinase domain but losing the N-terminal RAS-binding domain, 
suggesting that the mutant proteins may be constitutively active (Palanisamy, 
Ateeq et al. 2010).    
1.5.4 RAFs driven mouse lung tumor models  
In recent years, several mouse models have been developed to establish a 
causal relationship between MAPK mutations found in human lung cancer and 
tumor development (Karreth and Tuveson 2009). These models have contributed 
significant insights into the mechanisms of tumor formation and progression and 
are indispensable tools for preclinical testing of new therapeutic drugs (Schreck 
and Rapp 2006).  
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The first transgenic lung tumor models expressing RAF kinases were established 
in our lab by overexpression of wild type or constitutive active C-RAF (C-RAF 
BxB) under the control of the human Surfactant Protein-C promoter in lung 
alveolar epithelial type II cells (Kerkhoff, Fedorov et al. 2000). All mice expressing 
oncogenic C-RAF BxB develop benign adenomas within two weeks of age 
(Kerkhoff, Fedorov et al. 2000) (Rapp, Korn et al. 2009). RAF-induced lung 
tumors expand continuously without any sign of apoptosis (Schreck and Rapp 
2006) (Kerkhoff, Fedorov et al. 2000) and are highly dependent on MEK activity 
as treatment of mice with the CI-1040 (MEK) inhibitor led to reduced lung 
adenoma formation (Kramer, Gotz et al. 2004). More recently, based on the 
occurrence of B-RAF V600E mutations in NSCLC patients, many efforts were 
made to evaluate the role of this type of B-RAF mutation (B-RAF V600E) in lung 
tumor initiation and progression using mouse models. One of these models 
employed a knock-in strategy in which the oncogenic B-RAF allele is activated by 
infection of lungs with adenovirus expressing Cre-recombinase (Dankort, 
Filenova et al. 2007). These mice developed benign neoplastic adenomas in the 
lung that show some signs of senescence in the course of disease progression. 
However, in this study the tumor-initiating cell could not be identified due to the 
promiscuous target cell specificity of the activating virus (Dankort, Filenova et al. 
2007). In a second study Ji et al. used an inducible rat specific CCSP promoter 
that targets both bronchiolar Clara cells as well as a fraction of type II cells (Perl, 
Wert et al. 2005) for expression of B-RAF V600E. However, lung tumor formation 
in this model was only achieved in an Ink4A/Arf-/- background (Ji, Wang et al. 
2007).  
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1.6 Experimental design and aim of the project 
1.6.1 Lung-targeted expression of oncogenic B-RAF V600E  
Tissue- or cell-type-specific promoters allow restriction of the expression of the 
gene of interest to a tissue type in which the gene is known or suspected to be 
involved in transformation. In this project we aimed to evaluate the role of B-RAF 
V600E in lung tumor initiation and progression in vivo. For this purpose we have 
generated a novel transgenic mouse in which we have employed the Surfactant 
Protein C (SP-C) promoter to drive B-RAF V600E expression in epithelial type II 
pneumocytes, hypothetical cells of origin of NSCLC (figure 1.5). Using a similar 
strategy we have previously shown that lung alveolar type II cells respond to 
oncogenic C-RAF mediated activation of the mitogenic cascade with benign 
adenoma formation in the absence of additional genetic lesions (Kerkhoff, 
Fedorov et al. 2000). 
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Figure 1.5. Experimental strategy for lung-targeted expression of B-RAF V600E 
[modified from (Rawlins and Hogan 2006)]. Cartoon of a distal lung with a schematic 
representation of the targeting vector in which the Surfactant Protein C (SP-C) promoter 
drives the expression of oncogenic B-RAF V600E in alveolar epithelial type II cells. 
1.6.2 Elimination of B-RAF in a mouse model for NSCLC  
Conditional gene-targeting technology, in conjunction with regulatable systems, 
enables gene deletion in tissues of interest at specific times and eliminates 
concerns about potential embryonic lethality (O’Hagan, Wu et al. 2005). This 
analysis can be limited to selected tissues with appropriate engineering of the 
gene-targeting system (O’Hagan, Wu et al. 2005). Such knockout models can be 
interbred with cancer models to determine whether conditional gene deletion 
prevents tumor formation, inhibits progression, or causes regression of 
established tumors (Zambrowicz and Sands 2003).  
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Our lab has previously generated a mouse model for lung tumor development by 
expressing in type II pneumocytes an oncogenic N-terminal deleted form of C-
RAF (C-RAF BxB) (Kerkhoff, Fedorov et al. 2000). In vitro experiments have 
shown that B-RAF constitutively heterodimerize with C-RAF BxB by targeting its 
kinase domain and by activating it in the cytoplasm (Weber, Slupsky et al. 2001) 
(Garnett, Rana et al. 2005). Thus, B-RAF might be an important factor for the 
oncogenic activity of C-RAF BxB. In this project, we aimed to evaluate in vivo 
whether B-RAF is necessary for the transformation and/or growth of C-RAF BxB-
driven lung tumors. However, as already described, b-raf -/- mice die between 
embryonic day 11.5 (E11.5) and E12.5. Therefore, our laboratory has generated 
floxed-B-RAF mice to conditionally knock-out B-RAF in a tissue specific and in a 
time dependent manner. Conditional inactivation of B-RAF in lung tumors 
expressing oncogenic C-RAF was carried out by doxycyclin-induction of 
quadruple transgenic mice SpC-C-RAF BXB23/SpC- rtTA/Tet-O-cre/B-RAF flox/flox 
(figure 1.6). 
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Figure 1.6. Experimental strategy for conditional elimination of B-RAF in C-RAF 
BxB mediated lung tumors. In this system the SP-C promoter, which is active in type II 
cells, drives expression of both oncogenic C-RAF and the reverse tetracycline-controlled 
transcriptional activator (rtTA). When doxycyclin (DOX) is present the rtTA binds to the 
tetracycline response element (Tet-O) that leads to CRE-loxP-mediated deletion of the 
exon 3 of B-RAF and therefore absence of B-RAF protein.  
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2. Results (Lung-targeted expression of oncogenic B-
RAF V600E)  
2.1 Generation of transgenic mice with lung-targeted expression 
of B-RAF V600E  
2.1.1 Construction of SpC-B-RAF V600E plasmid 
SpC-B-RAF V600E plasmid was generated by releasing the 2,5 Kb human B-
RAF V600E cDNA from pKS-h B-RAF V600E (unpublished) by digestion with 
NotI restriction enzyme and inserted into SPC/SV40 plasmid (kindly obtained 
from Jeffrey Whitsett) that was previously digested with Bam HI endonuclease 
(figure 2.1). Prior to ligation, both vector and insert were blunt-ended with T4 
DNA polymerase.  
 
 
Figure 2.1. Schematic representation of the SpC-B-RAF V600E targeting vector. 
 
Correct orientation of the insert was tested by digestion with XhoI and SalI 
endonucleases and gel electrophoresis analysis. SpC-B-RAF V600E expression 
cassette (6,2 Kb) was resolved in a low melting agarose gel after digestion with 
Hind III restriction enzyme. The purified fragment was then injected into the 
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pronucleus of fertilized eggs of FVB/n mice. Dr. Rudolf Götz constructed the 
SpC-B-RAF V600E plasmid. Hildegard Troll carried out the pronuclear injection.  
2.1.2 Generation of SpC-B-RAF V600E transgenic mice 
We have generated three transgenic mouse founders for the expression of 
human B-RAF V600E under the control of the human SpC promoter. SpC-B-RAF 
V600E transgenic mice were born in the expected mendelian ratios, were fertile 
and did not show any gross morphological or behavioral abnormalities. Analysis 
of transgene expression levels among the founders showed comparable results 
(figure 2.2).  
 
 
Figure 2.2. Comparable levels of B-RAF V600E transgenic expression in the lung 
of the transgenic mouse founders. Analysis of B-RAF V600E mRNA levels between 
the founders (2 weeks old) by Real-time PCR, data represent mean + SEM, (t-test ns= 
not significant, n= 3). 
 
Histopathological analysis of lung sections from adult mice revealed airspace 
enlargements with various degrees in all the founders compared to control 
animals (figure 2.3). Interestingly lung tumor formation was not detected in any of 
Results (Lung-targeted expression of oncogenic B-RAF V600E) 
 
30 
 
these founders (figure 2.3). Based on the highest penetrance of alveolar 
enlargements, we have selected the founder line number 3 for further studies. 
 
 
Figure 2.3. Comparable formation of alveolar enlargements in SpC-B-RAF V600E 
transgenic founder lines. Representative paraffin embedded H&E stained lung 
sections from wild type and transgenic mice (2 months old), right panel pictures are high 
magnification of the red inserts, scale bar = 100 μm.  
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2.2 Characterization of SpC-B-RAF V600E transgenic mice 
2.2.1 Expression of B-RAF V600E in alveolar type II cells leads to 
airway enlargements in mice  
Consistent with the early expression of the transgene (figure 2.4A), we found 
airspace enlargements in the embryonic lung sections (figure 2.4B) that persisted 
in both post-natal and adult lungs of the transgenic animals (figure 2.4B). Some 
of these alveolar disruptions increased in size over time forming macroscopic air-
filled structures reminiscent of human bullous-emphysema (figure 2.4B-2.4C). 
The presence of these lesions affected the life span of animals (figure 2.4D). 
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Figure 2.4. Induction of airspace enlargements in mice with targeted expression of 
mutant B-RAF (V600E) in lung alveolar type II cells. (A) Semi-quantitative RT-PCR 
using species-specific primers shows transgenic- and endogenous- B-RAF expression in 
lungs of two wild type and transgenic embryos (E16.5), (cycles=PCR cycle; M=marker; 
h=human; m=mouse). (B) Paraffin embedded hematoxylin and eosin (H&E) stained lung 
sections from mice of different ages show airspace enlargements (arrows) in transgenic 
animals, (scale bar = 100 μm for the first, second and third panel; 1 mm for the forth 
panel). (C) Whole lung photographs of 4.5 months old wild type and transgenic mice 
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show macroscopic blebs (arrows). (D) Kaplan-Meier survival curves, (log-rank analysis P 
< 0.05; SpC-B-RAF V600E n = 59; wild type n = 30).  
  
For analysis of airspace enlargements, lungs from wild type and SpC-B-RAF 
V600E transgenic mice were evaluated blindly by two independent examiners. 
Tissue samples were graded in the following manner: 1) Micro- and macro- 
scopically normal; 2) Macroscopically normal, but microscopically abnormal 
[airspace enlargement]; 3) Macroscopic abnormalities [bulb formation] (figure 
2.5A). From all animals analyzed, only ~50% of SpC-BRAF V600E transgenic 
mice displayed grade 2 and grade 3 lesions (~25% each group), respectively 
(figure 2.5A-2.5B). The lungs of all wild type mice analyzed were graded as 
1(figure 2.5A-2.5B). However, ~50% of the transgenic mice analyzed were 
apparently similar to wild type (figure 2.5A-2.5B). All immunohisopathological 
analysis that will be described in the following chapters were performed on lung 
sections of transgenic animals carrying grade 2 and grade 3 lesions.    
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Figure 2.5. Scoring of B-RAF V600E induced lung lesions in transgenic mice. (A) 
Representative pictures of H&E stained lung sections from wild type and transgenic mice 
show airspace enlargements with different grades. The scoring was performed as 
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follows: 1) Micro- and macro-scopically normal; 2) Macroscopically normal, but 
microscopically abnormal [airspace enlargement]; 3) Macroscopic abnormalities [bulb 
formation, pointed by arrows]. Scale bar= 1 mm for low magn. and 100 µm for high 
magn. pictures. (B) Incidence of the lung lesions with different grades, (n=59 for wild 
type, n=102 for SpC-B-RAF V600E).  
 
2.2.2 Increased apoptosis and absence of MAPK signaling 
activation  
To characterize the observed defect in lung development at the molecular and 
cellular level, we first examined the apoptotic and proliferative rate of the lung 
epithelium. We therefore screened lung sections from SpC-B-RAF V600E 
transgenic mice of different ages for apoptosis and proliferation markers. We 
found increased active caspase 3 staining in lung sections from transgenic mice 
only at postnatal day 1 (figure 2.6A-2.6B). There was no change in cell 
proliferation assessed by Ki67 immunostaining at this age (figure 2.6C-2.6D). 
However we found a significant increased in cell proliferation in lungs of 
transgenic mice at postnatal day 14 (figure 2.6C-2.6D).  
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Figure 2.6. Analysis of cell death and cell proliferation in transgenic mice. (A) 
Active caspase 3 staining of control and transgenic animals, (arrows indicate positive 
cells), (E= embryonic, P=post-natal), (hematoxylin was used as a counterstain); scale 
bar= 50 μm. (B) Quantitation of active caspase 3 staining. (C) Ki67 staining (brown) of 
control and transgenic animals, (E= embryonic, P= post-natal), (hematoxylin was used 
as a counterstain); scale bar= 50 μm. (D) Quantitation of Ki67 staining. For quantitation 
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of apoptosis and cell proliferation, at least 4 mice were used for each time point. Values 
represent mean + SEM, (t-test *= P < 0.05, ns= not significant).  
 
Consistent with the increased rate of apoptosis we observed diminished levels of 
transgene expression in adult mice (figure 2.7A). Furthermore, neither total B-
RAF nor phospho-ERK protein levels altered between the wild type and 
transgenic mice (figure 2.7B). 
 
Figure 2.7. Diminished transgene expression and lack of phospho-ERK 
upregulation in SpC-B-RAF V600E mice. (A) Semi quantitative RT-PCR analysis total 
lung RNA samples from wild type (wt) and transgenic (tg) animals shows different levels 
of transgene expression between embryonic and adult mice, HPRT was used as an 
internal control, (h.=human). (B) Total lung protein lysates from two wild type (wt) and 
transgenic (tg) littermates were gel separated and immunoblotted; ages and antibodies 
are as indicated.   
 
Immunohistochemical analysis of lung sections for lung differentiation markers 
showed the presence of epithelial cell types from the distal lung, including Clara 
cells, type I and type II pneumocytes (figure 2.8). Notably, the lung lesions were 
often found to be continuous with bronchio-alveolar junctions (figure 2.8). 
Moreover we found a significant fraction of proliferating cells (figure 2.8).  
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Figure 2.8. Immunohistochemical analysis of lung lesions for lung differentiation 
markers.  Paraffin embedded lung sections from wild type and transgenic mice at 2 
months of age were stained for indicated markers; (green arrows point out airspace 
enlargements), (the red arrow marks the bronchio-alveolar junction), (red-parenthesis 
indicates a AQP5 negative sector), (red arrowheads point to Pro-SPC expressing cells), 
(black arrows highlight Ki67 positive cells), (Br= bronchiole), (hematoxylin was used as a 
counterstain), (right panel pictures are high magnification of the red insets); scale bar = 
100 μm.  
 
2.2.3 Signs of tissue remodeling   
Airway and lung tissue remodeling and fibrosis play an important role in the 
development of symptoms associated with lung function loss such as 
bronchopulmonary dysplasia and COPD (Postma and Timens 2006). Since SpC-
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B-RAF V600E animals display some features of these diseases such as airspace 
enlargements, we thought to search for fibrosis marker in the lung of our 
transgenic mice. Interestingly, we found progressive deposition of collagen (figure 
2.9) in non-epithelial lining sectors of the emphysematous lesions (figure 2.8, red 
parenthesis) indicating an ongoing tissue remodeling.  
 
Figure 2.9. Masson´s Trichrome staining shows progressive collagen (blue) 
accumulation in the lung of SpC-B-RAF V600E transgenic mice, red-parenthesis 
indicates Masson´s Trichrome negative parts, (the right panel pictures are high 
magnification of the red inserts); scale bar = 100 μm. 
 
Bronchiolar hypertrophy and mucus hypersecretion are other prominent features 
of various human lung disease (Barnes 2000); we therefore stained lung sections 
from wild type and SpC-B-RAF V600E transgenic mice with Alcian Blue pH 2.5 
solution for the detection of acidic mucins. Interestingly, we found an age-related 
increase in mucus secretion in transgenic mice (figure 2.10).  
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Figure 2.10. Goblet cell hyperplasia in aged SpC-B-RAF V600E transgenic mice. (A) 
Representative pictures of Alcian blue stained paraffin embedded lung sections from wild 
type and transgenic mice at 3 and 12 months of age, respectively, black arrowheads 
denote Alcian Blue-positive (blue) regions indicative of increased mucus production; 
scale bar = 100 μm. (B) Quantification of Alcian Blue positive bronchiole in wild type (n= 
6-8) and SpC-B-RAF V600E (n= 7-8) transgenic mice at young (1-3 months) and older 
(4-28 months) ages (t-test *= P < 0.05, ns= not significant). 
 
Epithelial-Mesenchymal-Transition (EMT) was often shown to be associated with 
chronic human lung diseases such as COPD and pulmonary fibrosis (Holgate, 
Davies et al. 2000; Flanders 2004; Willis and Borok 2007; Lee, Walser et al. 
2009). We therefore analyzed total lung tissue lysates of SpC-B-RAF V600E 
transgenic mice, which harbored macroscopic lung lesions (grade 3) with known 
EMT markers. We found reduced expression of E-cadherin, ß-catenin and 
increased expression of Vimentin, indicating EMT induction (figure 2.11A), 
although we cannot rule out the induction of an alveolar maintenance program in 
alveolar type II cells (Yildirim, Muyal et al. 2010). Expression of Vimentin was not 
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solely localized next to the emphysemic lesions but also abundantly found in 
fibrotic lung parenchyma (figure 2.11B). Since the transgenic lungs show 
airspace enlargement and inflammation, these results could simply reflect the 
relative changes in cell populations in the lung rather than an EMT phenomenon. 
We therefore analyzed the same markers in isolated alveolar type II cells from 
mice that in this case did not show macroscopic lesions by Real-Time PCR and 
immunoblotting. We found significantly reduced E-cadherin and increased 
Vimentin mRNA levels in isolated type II cells from SpC-B-RAF V600E mice 
(figure 2.11C). Different from the mRNA data, we detected equal to mildly 
decreased levels of E-cadherin in protein lysates of type II cells from transgenic 
animals (figure 2.11D). In contrast, variable levels of vimentin expression were 
detected between the samples (figure 2.11D). As in the case of the total lung 
lysates we observed strongly reduced levels of ß-catenin in type II cells from 
mutant mice (figure 2.11A and 2.11D). In addition to ß-catenin, the levels of 
p120ctn were also reduced (figure 2.11D). ß-catenin is a key signaling mediator of 
the canonical WNT signaling (Mucenski, Wert et al. 2003). Interestingly, in both 
total lung and isolated type II cells protein lysates from SpC-B-RAF V600E mice 
we detected diminished levels of active ß-catenin expression suggesting an 
inhibition of the canonical WNT signaling pathway (figure 2.11A and 2.11D).   
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Figure 2.11. Analysis of Epithelial-Mesenchymal-Transition (EMT) in SpC-B-RAF 
V600E transgenic mice. (A) Total lung protein lysates from two wild type (wt) and 
transgenic (tg) littermates (17 and 21 months old) were gel separated and 
immunoblotted with the indicated antibodies. (B) Immunostaining of lung sections from 
wild type and SpC-B-RAF V600E transgenic mice for Vimentin (brown), (E= airspace 
enlargement), hematoxylin was used as a counterstain, scale bar = 100 μm. (C) Analysis 
of E-cadherin and Vimentin mRNA levels in alveolar type II cells isolated from wild type 
and SpC-B-RAF V600E transgenic mice (5 months old) by Real time PCR, data 
represent mean + SEM, (t-test *= P < 0.05, **= P < 0.01, n= 3-4). (D) Protein lysates of 
isolated type II cells from two wild type (wt) and transgenic (tg) littermates (20 months 
old) were gel separated and immunoblotted with the indicated antibodies.  
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2.2.4 Induction of inflammation  
Chronic inflammation is a prominent feature of degenerative lung diseases in 
human (Qu, Roberts et al. 2009). In order to assess the infiltration of immune 
cells, we screened lung sections from young (1-3 months) and aged (4-28 
months) mice using different immune cell markers. Progressive accumulations of 
infiltrating macrophages were observed in the vicinity of the lung lesions (figure 
2.12A and 2.12B). In extreme cases, these massive accumulations led to the 
formation of granulomas that filled almost the whole lung parenchyma (figure 
2.12A, 12 months). 
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Figure 2.12. Progressive accumulation of macrophages in the lung of SpC-B-RAF 
V600E transgenic mice as a function of age. (A) Paraffin embedded lung sections 
from mice with indicated genotypes and ages stained for F4/80 (brown), E= airspace 
enlargement, arrowheads show scattered alveolar macrophages, hematoxylin was used 
as counterstain, scale bar = 100 μm. (B) Quantification of F4/80 positive macrophages in 
wild type (n= 9) and SpC-B-RAF V600E (n= 9) transgenic mice at young (1-3 months) 
and older (4-28 months) ages (t-test *= P < 0.05, ns= not significant).  
 
Interestingly mast cells were detected in the walls lining the enlarged air spaces 
(figure 2.13A). Moreover, we found an increased incidence of lymphoid 
aggregates in SpC-B-RAF V600E transgenic mice (figure 2.13B and 2.13C). 
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Figure 2.13. Infiltration of immune cells in emphysema-like lesions. (A) Toluidine 
blue staining identifies mast cells (purple) in the epithelial lining of a lesion. (B) Staining 
of paraffin embedded lung sections from wild type and transgenic mice for CD45 
(brown), hematoxylin was used as counterstain, the right panel pictures are high 
magnification of the red insets; scale bar = 100 μm. (C) Lymphoid aggregate incidence in 
lung sections from wild type (1-3 months n=16, 4-28 months n=28) and SpC-B-RAF 
V600E (1-3 months n=17, 4-28 months n=52) transgenic mice. 
Immunohiostochemical analysis of lung sections with lymphoid clusters from 
SpC-B-RAF V600E transgenic mice revealed that these follicles are mostly 
composed of T- and B-lymphocytes (figure 2.14).   
 
Figure 2.14. Presence of T- and B- cells in CD45 positive clusters. Lung sections 
from SpC-B-RAF V600E transgenic mice were stained for CD3 and PAX5 to identify T- 
and B- cells, respectively; hematoxylin was used as a counterstain; scale bar= 100 μm.    
 
Interestingly, in rare extreme cases, these lymphoid aggregates reached very 
large sizes occupying most of the air exchange space of the entire lung (figure 
2.15A). Moreover, these CD45 positive clusters were found to be surrounded by 
intense collagen accumulations (figure 2.15B). 
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Figure 2.15. Severe lung degeneration in an aged (17.5 months) mouse transgenic 
for B-RAF V600E. (A) H&E staining of a lung section shows massive infiltration of 
leukocytes (red arrows). (B) Masson´s Trichrome staining of the consecutive lung section 
reveals collagen-enriched regions (blue), the right panel pictures are high the 
magnification of the yellow inserts; scale bar=1 mm for the left and 100 μm for the right 
panel.  
In order to identify the mechanisms by which B-RAF V600E triggers 
inflammation, IL-6/signal transducer and activator of transcription 3 (STAT3), a 
well known inducer of inflammation (Jarnicki, Putoczki et al. 2010), was studied. 
Western blot analysis of lung protein lysates showed up-regulation of phospho-
STAT3 in transgenic animals (figure 2.16A). Immunostaining of lung sections with 
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phospho-STAT3 specific antibody showed similar results indicating the activation 
of STAT3 signaling in SpC-B-RAF V600E mice (figure 2.16B). 
 
Figure 2.16. Activation of STAT3 signaling in SpC-B-RAF V600E transgenic mice. 
(A) Total lung protein lysates from two wild type (wt) and transgenic (tg) littermates (17 
and 21 months old) were gel separated and immunoblotted with the indicated antibodies. 
(B) Phospho-STAT3 immunostaining of lung sections shows accumulation of pSTAT3 
positive cells in transgenic mice (arrows point to a macroscopic bleb, arrowheads point 
to pSTAT3 positive cells), hematoxylin was used as a counterstain, scale bar = 1 mm in 
the right and 100 μm in the left panel pictures.   
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2.2.5 Synergistic effect of oncogenic B- and C-RAF in SpC-B-
RAF V600E/SpC-C-RAF BxB 23 compound mice 
In order to test whether the lack of early adenoma formation in our SpC-B-RAF 
V600E transgenic mouse is a consequence of an acquired tumor resistance in 
the founders, the mice were crossed with transgenic animals that develop 
oncogenic-C-RAF driven adenomas originating in type II pneumocytes (Kerkhoff, 
Fedorov et al. 2000).  
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Figure 2.17. Independence of emphysema-like lesions and adenoma-formation in 
SpC-B-RAF V600E / SpC-C-RAF BxB23 compound mice. (A) H&E staining of lung 
sections reveal both types of pathology. (Red arrows indicate individual adenomas; 
green arrow indicates emphysema-like lesions; genotype and ages are as indicated; 
scale bar= 100 μm). (B) Quantitation of tumor load and tumor size as a function of age. 
(Mean values are ± SEM; ns= not significant; **= P<0.005; ***=P<0.0005). 
 
As reported in figure 2.17, coexpression of oncogenic B- and C-RAF transgenes 
showed that the two transgene-driven lesions are co-dominant (figure 2.17A). 
Indeed, tumor load and tumor size are indistinguishable between SpC-C-RAF 
BxB 23 single and compound double transgenic animals (figure 2.17B). B-RAF 
V600E is a very potent activator of the mitogenic cascade; we therefore 
compared nuclear pERK levels and found no differences between lung tumors in 
single and compound transgenic mice (figure 2.18A and 2.18B). Finally, we found 
no difference in the life span between single transgenic and compound mice 
(figure 2.18C). Altogether these data indicate that oncogenic B- and C-RAF do 
not cooperate during disease progression.     
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Figure 2.18. Presence of B-RAF V600E transgene does not alter phospho-ERK 
levels in SpC-C-RAF BxB23 driven adenomas. (A) phospho-ERK immunostaining for 
the indicated genotypes. (Compound= SpC-B-RAF V600E / SpC-C-RAF BxB23 double 
transgenic mice; red-arrowheads marks cells with high nuclear pERK; hematoxylin was 
used as counter stain; scale bar= 100 μm). (B) Quantitation of nuclear pERK staining. 
(Mean values are ± SEM; ns= not significant). (C) Kaplan-Meier survival curves, (log-
rank analysis P > 0.05; Compound n = 32; SpC-C-RAF BxB23 n = 27).  
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2.2.6 Delayed tumor formation in SpC-B-RAF V600E transgenic   
As there is a large body of clinical evidence that human chronic lung diseases 
may be linked with the late onset of lung cancer (de Torres, Bastarrika et al. 
2007) (Wilson, Weissfeld et al. 2008), we looked at a cohort of aged mice for lung 
tumor formation. In comparison to wild type control littermates, we detected 
single focal lung tumors with low incidence (~10%) in SpC-B-RAF V600E 
transgenic mice (figure 2.19A and 2.19B). Notably, tumors were always found in 
lungs with airspace enlargements (figure 2.19B). Lung tumors stained positive for 
TTF-1, Pro-SPC, and Aquaporin-5 and negative for CCSP indicating a type II 
pneumocyte origin (figure 2.19C). Immunohistochemical analysis of tumors with 
the components of mitogenic cascade signaling showed positive staining for both 
B-RAF and phospho-ERK1/2 but not for C-RAF (figure 2.19C).  
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Figure 2.19. Lung tumor formation in SpC-B-RAF V600E transgenic mice. (A) 
Tumor incidence as a function of age, log-rank analysis for wild type (n = 59) and SpC-B-
RAF V600E (n = 102) transgenic mice, P < 0.05. (B) H&E staining of lung section from a 
one year old SpC-B-RAF V600E transgenic mouse shows coexistence of the lung 
lesions (arrowheads) with a lung tumor (arrow); scale bar= 500 µm. (C) Tumor bearing 
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lung sections were stained with the indicated markers, hematoxylin was used as 
counterstain; scale bar = 100 μm.  
 
Low incidence and late latency of lung tumors from SpC-B-RAF V600E mice are 
in the favor of a spontaneous origin. We therefore screened tumor samples for 
somatic mutations that are commonly found in human and mouse NSCLC 
(Forbes, Bindal et al. 2011). Interestingly the majority of the tumors were negative 
for these mutations (figure 2.20).  
 
 
Figure 2.20. Lung tumors found in SpC-B-RAF V600E transgenic mice in general 
do not harbor mutations frequently present in human and mouse NSCLC. Genomic 
DNA from both lung tumors and matched histological normal lung tissue of SpC-B-RAF 
V600E transgenic mice were screened for the indicated genes, individual animal (ID) and 
Exon numbers are as indicated, wt= wild type, Hetero=heterozygous, 
Homo=homozygous, empty boxes represent untested samples.  
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2.2.7 T- and B-lymphocytes are not involved in the development 
of COPD-like lesion and lung tumor 
In order to evaluate the potential role of the adaptive immunity in the 
development of COPD-like lesions, SpC-B-RAF V600E single transgenic mice 
were crossed with RAG1-null mice that lack mature T- and B- lymphocytes 
(Mombaerts, Iacomini et al. 1992). Histological examination of lung sections from 
compound mice (SpC-B-RAF V600E / RAG1 KO) demonstrated persistence of 
COPD-like lesions indicating that T- and B- cells are not involved in the lung 
pathogenesis in our system (figure 2.21A and B). 
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Figure 2.21. Mature T- and B- cells are not required for the formation of COPD-like 
lesions in SpC-B-RAF V600E transgenic mice. (A) H&E staining of lung sections from 
wild type, RAG1 knock out (KO), SpC-B-RAF V600E single transgenic and SpC-B-RAF 
V600E/RAG1 KO compound animals show persistence of lung lesions in SpC-B-RAF 
V600E single and compound mice, green arrows point to airspace enlargements. (B) 
Immunostaining of paraffin embedded lung sections from RAG1 KO single transgenic 
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and SpC-B-RAF V600E/RAG1 KO compound animals for CD45 (brown), red arrows 
point to CD45 positive clusters, hematoxylin was used as counterstain; scale bar= 100 
μm.   
Moreover, the late development of lung tumors with incomplete penetrance in 
compound animals supports this data (figure 2.22). 
 
Figure 2.22. Delayed lung tumor formation in SpC-B-RAF V600E/RAG1 KO 
compound mice with incomplete penetrance. H&E staining of lung section from a 5 
months old SpC-B-RAF V600E/RAG1 KO compound mouse shows an adenoma; scale 
bar= 100 μm.  
 
3. Discussion (Lung-targeted expression of oncogenic 
B-RAF V600E) 
Mutations in the components of the mitogenic cascade play an important role in 
both developmental syndromes and neoplastic diseases (Schubbert, Bollag et al. 
2007). Individuals with these syndromes often have mutations in this signaling 
pathway that predisposes them to cancer too (Schubbert, Bollag et al. 2007). 
NSCLC is the leading cause of cancer related death worldwide and frequently 
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harbors activating mutations in the MAPK pathway (Ding, Getz et al. 2008). A 
fraction (~ 2%) of NSCLC patients harbor B-RAF mutations (Forbes, Bindal et al. 
2011) and several previous studies attempted to model human NSCLC in mice. 
They have shown that conditional expression of B-RAF V600E rapidly induces 
lung adenoma formation (Dankort, Filenova et al. 2007; Ji, Wang et al. 2007). 
However, in our study, constitutive expression of this mutant B-RAF in type II 
pneumocytes did not elicit immediate tumor formation but predominantly caused 
airspace enlargements which were often associated with inflammation. Lack of 
tumor formation in SpC-B-RAF V600E transgenic mice in comparison to the SpC-
C-RAF BxB mice (Kerkhoff, Fedorov et al. 2000) is intriguing, as both oncogenes 
are known to activate the mitogenic cascade. It is plausible that the diminished 
transgene expression caused by the induction of apoptosis during lung 
development precluded oncogenic transfomation of alveolar type II cells. The 
absence of elevated phospho-ERK levels in transgenic mice supports such a 
hypothesis. Alternatively, as reported previously, induction of cellular senescence 
program by oncogenic B-RAF may restrict expansion of transformed cells 
(Michaloglou, Vredeveld et al. 2005). However, we did not find detectable levels 
of p16INK4a, p21WAF1 and p19ARF, the common oncogene-induced senescence 
markers, protein expression neither by immunoblotting nor by 
immunohistochemistry in transgenic mice from different ages (data not shown).   
In the present study, the expression of B-RAF V600E specifically in alveolar type 
II cells during lung development affected alveolar formation. Earlier studies 
showed that the canonical WNT signaling plays a crucial role during lung 
development (Mucenski, Wert et al. 2003). Inhibition of WNT signaling by 
conditional knockout of ß-catenin in alveolar type II cells disrupted lung 
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morphogenesis and caused respiratory failure due to dilated terminal structures 
in their lungs (Mucenski, Wert et al. 2003). The airway space enlargements that 
we find in our transgenic mice may be related to the downregulation of WNT 
signaling that we detected in isolated type II pneumocytes. Interestingly, similar to 
oncogenic B-RAF, activation of oncogenic K-rasG12D, the most frequent mutation 
found in human NSCLC, was shown to impair lung morphogenesis by up-
regulating Ras/MAPK antagonist Sprouty-2 in the absence of apoptosis (Shaw, 
Meissner et al. 2007). It remains to be elucidated whether Sprouty-2 or other 
antagonists of the mitogenic cascade play a role in generation of developmental 
defects induced by B-RAF V600E in our transgenic model.  
The airspace enlargements observed in embryonic lungs of SpC-B-RAF V600E 
transgenic mice were maintained in adult animals and were associated with 
tissue remodeling and chronic inflammation. Accumulations of collagen and 
mucus secretion that we found in transgenic lungs suggest that there is an 
ongoing tissue repair. However, persistence of the lung lesions throughout the 
lifetime of the animals indicates that there is an inefficient recovery of the lung 
epithelium. Inhibition of canonical WNT signaling as well as absence of full EMT 
in lungs of transgenic animals may account for incomplete repair. Chronic 
inflammation plays also an important role in tissue remodeling by promoting the 
release of cytokines by immune cells (Curtis, Freeman et al. 2007). STAT3, a 
cytokine-induced gene related to pulmonary inflammation in human COPD, has 
been shown to be required for alveolar structure maintenance and function (Li, 
Du et al. 2007). Persistent activation of the STAT3 signaling in murine respiratory 
epithelial cells was also shown to induce pulmonary inflammation and tumor 
formation in the lung (Li, Du et al. 2007). Moreover STAT3 is a potent mediator of 
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pro-inflammatory interleukin 6 (IL-6) that was shown to induce EMT phenotype in 
human breast cancer cells (Sullivan, Sasser et al. 2009). Abundant expression of 
activated STAT3 that we found in lungs of SpC-B-RAF V600E transgenic mice 
may indicate a role for STAT3 in the promotion of tissue remodeling and 
inflammation in our system. 
Histopathological analysis of the infiltrating immune cells present in SpC-B-RAF 
V600E transgenic mice demonstrated the recruitment of inflammatory cells from 
both innate and adaptive immune system. The increase in occurrence of 
lymphoid aggregates consisting of T- and B-cells raises the question whether 
there was a specific immune response to B-RAF V600E. We have previously 
described a T-cell specific epitope of B-RAF V600E (Andersen, Fensterle et al. 
2004) that could be involved in immune selection, suggesting that the immune 
response might be the driving force behind the development of these lesions in 
the transgenic animals. However, lack of immune cells in embryonic lungs with 
airspace enlargements and persistence of these lesions in lungs from SpC-B-
RAF V600E / RAG1-null compound mice suggest that cells of the adaptive 
immune system are dispensable in the course of the disease. In fact, cells from 
the innate immune system; such as macrophages and mast cells were 
abundantly found in the lung of our transgenic animals. The progressive 
accumulation of macrophages as well as lymphoid aggregates might contribute to 
an elevated mucus production and increased damage observed in these lesions. 
In addition to macrophages, mast cells have important roles in innate immunity 
and tissue remodeling but so far, they have been poorly studied in human COPD 
(Andersson, Mori et al. 2010). Our data suggest that mast cells might play a role 
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in the progression of chronic lung degeneration and therefore should be 
examined in more detail in future.  
It has been previously shown that the expression of B-RAF V600E in lung 
epithelial cells induced lung tumor formation. In contrast to these previous 
studies, we found that the early expression of mutant B-RAF in alveolar type II 
cells caused airspace enlargements in the absence of lung tumors. The 
differences between these models might result from a different targeting strategy, 
as well as different timing of oncogene induction (Dankort, Filenova et al. 2007) 
(Ji, Wang et al. 2007). Nevertheless we detected lung tumors with low incidence 
only in aged transgenic animals. The presence of single focal tumors with low 
penetrance in transgenic mice suggests a spontaneous origin. However, the rate 
of spontaneous tumor formation in transgenic mice was significantly higher than 
in C57BL/6 mice (Krupke, Begley et al. 2008). Consistent with the link between 
inflammation and cancer, the increased number of spontaneous lung tumors 
found in SpC-B-RAF V600E mice might be due to inflammation that was often 
associated with the airspace enlargements.  
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4. Results and discussion (Elimination of B-RAF in a 
mouse model for NSCLC) 
4.1 Rationale 
Tumors often are highly dependent on signaling pathways promoting cell growth 
or survival and may become hypersensitive to downregulation of key components 
within these signaling cascades (Gotz, Kramer et al. 2004). RAF and Ras 
mutations found in human malignancies convey constitutive activity to these 
signaling molecules thereby converting them into an oncogenic state (Davies, 
Bignell et al. 2002). Non-sense point substitutions are the most frequent type of 
RAF mutations in human cancer. Recently, chromosomal translocations involving 
either B- or C-RAF in a small percentage of several type of cancers were found 
(Palanisamy, Ateeq et al. 2010) (McMahon 2010). Notably, these gene fusions 
encode for RAF proteins retaining the kinase domain but losing the N-terminal 
RAS-binding domain, suggesting that the mutant proteins may be constitutively 
active (Palanisamy, Ateeq et al. 2010). 
Previously, our lab has generated a mouse lung tumor model by targeting an 
active C-RAF (C-RAF BxB) to type II cells using the SP-C promoter. C-RAF BxB 
lacks the regulatory NH2-terminal sequences including the Ras interaction 
domain (Kerkhoff, Fedorov et al. 2000). Cell culture experiments showed that C-
RAF BxB constitutively associates with B-RAF in a Ras-independent manner 
(Weber, Slupsky et al. 2001). These data may suggest that the C-RAF BxB/B-
RAF heterodimerization is necessary for the oncogenic properties of C-RAF BxB.       
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4.2 Oncogenic C-RAF cooperates with B-RAF in lung tumor 
growth 
In order to evaluate in vivo the role of B-RAF in oncogenic-C-RAF mediated lung 
tumorigenesis, conditional B-RAF gene inactivation using a DOX inducible 
Cre/loxP site-specific recombination system was employed (figure 1.6). Lung 
specific ablation of B-RAF was detected in SpC-C-RAF BXB/SpC- rtTA/Tet-O-
cre/B-RAF flox/flox compound mice that were induced with doxycyclin (DOX) 
throughout gestation and until the day of sacrification (figure 4.1).  
 
 
Figure 4.1. Specific recombination of the conditional B-RAF allele in the lung of 
DOX-induced compound mice. DNA was extracted from the indicated tissues of two 
months old animals and subjected to PCR using primers that detect the conditional B-
RAF allele in the germline (B-RAF flox) or recombined (B-RAF Δ) state. PCR products 
were resolved on agarose gel electrophoresis and photographed.    
In order to assess the effect of B-RAF loss on lung tumorigenesis, compound 
mice were DOX-treated throughout gestation until 2, 7 and 12 months 
respectively; and subsequently examined by histology. Interestingly, all 
compound animals displayed lung tumors (figure 4.2A and B). We found no 
difference in the tumor incidence of DOX-induced SpC-C-RAF BXB/SpC- 
rtTA/Tet-O-cre/B-RAF flox/flox compound mice and aged-matched controls at 2 and 
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7 months of age (figure 4.2B). However, we observed a significant reduction in 
the lung tumor growth only in DOX-induced compound animals (figure 4.2C).  
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Figure 4.2. Oncogenic C-RAF BxB cooperates with B-RAF in lung tumor growth 
but not in tumor incidence. (A) Representative pictures of H&E stained lung sections 
from DOX-induced (SpC-C-RAF BXB/SpC- rtTA/Tet-O-cre/B-RAF flox/flox) compound mice 
and aged-matched controls, genotypes and ages are as indicated, red arrows point to 
lung adenomas. (B and C) Analysis of tumor incidence and tumor volume in compound 
mice; genotypes, induction status and ages are as indicated; tumor volume was 
calculated by assuming a spherical shape (for details on quantification methods see 
material and methods section). (Mean values are + SEM; t-test ns= not significant; ***= 
P<0.0005).    
Although reduced in size, the tumors of DOX-induced compound animals were 
well differentiated as judged by their cell morphology and immunostaining of two 
tumor markers (pan-Cytokeratine and Pro-SPC) (figure 4.3). 
 
Figure 4.3. Pan-Cytokeratine and Pro-SPC expression in lung tumors of DOX-
induced and controls compound mice. Representative pictures of paraffin embedded 
lung sections from 7 months old DOX-treated (SpC-C-RAF BXB/SpC- rtTA/Tet-O-cre/B-
RAF flox/flox) and controls animals that were stained with the indicated markers (brown). 
The genotypes are as indicated.    
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4.3 Reduced cell proliferation in lung tumors lacking B-RAF 
The reduced tumor growth in oncogenic-C-RAF driven lung tumors, which lack B-
RAF, could be either a consequence of reduced cell proliferation or an increase 
in apoptosis or even a combination of both. We therefore screened tumor bearing 
lung sections from DOX-induced SpC-C-RAF BXB/SpC- rtTA/Tet-O-cre/B-RAF 
flox/flox and aged-matched compound mice with markers of both proliferation and 
apoptosis. Ki67 and phospho-H3 stainings clearly showed a strong reduction of 
cycling cells upon B-RAF ablation in C-RAF BxB induced lung tumors (figure 
4.4A and B). TUNEL and active caspase 3 stainings instead did not exhibit any 
difference between DOX-induced and control animals (figure 4.4C and D). No 
decrease in the number of lung tumors between 2 and 7 months and the absence 
of apoptosis argue against cell death mechanisms as responsible for the slow 
tumor growth after B-RAF elimination (figure 4.2A and B) (figure 4.4C and D).   
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Figure 4.4. Reduced proliferation and absence of apoptosis in C-RAF BxB driven 
lung tumors lacking B-RAF. SpC-C-RAF BXB/SpC- rtTA/Tet-O-cre/B-RAF flox/flox 
compound mice were DOX-induced for 7 months and compared to aged-matched 
controls. Representative pictures and quantification of Ki67 (A), phospho-H3 (B), TUNEL 
(C) and active caspase 3 (D) staining (brown) of paraffin embedded lung sections. 
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Genotype and induction status are as indicated, red arrows point to positively stained 
cells. (n=75, mean values are + SEM; t-test ns=not significant, ***=P<0.0005). 
 
4.4 B-RAF cooperates with oncogenic C-RAF in the activation of 
the MAPK cascade 
In line with recombination of the B-RAF allele (figure 4.1), immunohistochemical 
analysis of tumor bearing lung sections showed the loss of B-RAF protein only in 
adenomas of DOX-induced SpC-C-RAF BXB/SpC- rtTA/Tet-O-cre/B-RAF flox/flox 
compound mice (figure 4.5A). Not all tumors of DOX-induced compound mice 
displayed the loss of B-RAF expression indicating that these tumors were 
“escapers” of the cre-mediated recombination (data not shown). Reduction of 
tumor growth in DOX-induced compound animals could be a consequence of 
transgene shutdown upon B-RAF ablation. However, staining of lung sections 
with a C-RAF antibody showed the transgene expression (figure 4.5A). 
Nevertheless, the levels of nuclear phospho-ERK were reduced in lung tumors of 
DOX-induced compound mice indicating that B-RAF cooperates with C-RAF BxB 
in the activation of the mitogenic cascade (figures 4.5A and B). Immunoblotting 
experiments using protein lysates from total lung of 7 months old DOX-induced 
SpC-C-RAF BXB/SpC- rtTA/Tet-O-cre/B-RAF flox/flox and 2 months control mice 
confirmed these findings (figure 4.5C). These results are in line with previous 
biochemical data showing that B-RAF heterodimerize with C-RAF by targeting its 
kinase domain and by activating it in the cytosol in a RAS-independent manner 
(Garnett, Rana et al. 2005).  
It is conceivable that the reduced tumor growth in oncogenic-C-RAF driven lung 
cancer that lack B-RAF is caused by a reduction in signaling through the 
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mitogenic cascade. However, since all DOX-induced compound mice that we 
analyzed developed lung tumors we can speculate that in vivo B-RAF is a 
dispensable factor in the oncogenic properties of C-RAF BxB.  
 
Figure 4.5. B-RAF cooperates with C-RAF BxB in the activation of the MAPK 
cascade. (A) Paraffin embedded lung sections from 7 months old DOX-treated and 
controls (SpC-C-RAF BXB/SpC- rtTA/Tet-O-cre/B-RAF flox/flox) compound mice were 
stained with the indicated markers (brown), red arrows point to tumors cells which 
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display nuclear phospho-ERK staining (brown), hematoxylin was used as counterstain. 
(B) Quantification of nuclear phospho-ERK staining shown in A, genotypes and induction 
status are as indicated. (n=40, mean values are + SEM; t-test ***=P<0.0005). (C) Total 
lung protein lysates from 7 months DOX-treated and 2 months control compound mice 
were gel separated and immunoblotted with the indicated antibodies; age, genotype and 
induction status are as indicated.   
 
Recently, Blasco et al. demonstrated in mouse models that C-RAF, but not B-
RAF, is essential for the development of oncogenic-K-Ras-driven NSCLC 
(Blasco, Francoz et al. 2011). Interestingly, in this work, the elimination of B-RAF 
expression had no effect on the levels of MEK and ERK phosphorylation 
suggesting that other RAF proteins can maintain mitogenic signaling (Blasco, 
Francoz et al. 2011). Instead, our data underline the importance of B-RAF in C-
RAF BxB-mediated neoplastic transformation.  B-RAF/C-RAF BxB 
heterodimerization seems to be necessary for the full activation of the mitogenic 
cascade.  
Our lab has previously shown that the RAF inhibitor BAY 43-9006 was not 
efficient in the inhibition of lung adenomas in SpC-C-RAF BxB23 transgenic mice 
(Kramer, Gotz et al. 2004). Several biochemical assays have shown that the BAY 
43-9006 is a very potent inhibitor of the catalytic domain of C-RAF, wild type B-
RAF, B-RAF V600E and also different receptor tyrosine kinases (Wilhelm, Carter 
et al. 2004). Recently, many novel data on a new and more specific RAF inhibitor 
(PLX4032) have shown that although this inhibitor is active against tumors with 
mutant RAFs (such as B-RAF V600E), it does not suppresses the growth of 
tumors with mutant Ras or wild type B-RAF. Indeed, this inhibitor can activate the 
MAPK cascade through homo- or heterodimerization mechanisms of B- and C-
RAF in a Ras-dependent manner (Poulikakos, Zhang et al. 2010) (Heidorn, 
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Milagre et al. 2010) (Hatzivassiliou, Song et al. 2010). So why is the BAY 43-
9006 inhibitor not active in our RAF dependent lung tumor mouse model (Kramer, 
Gotz et al. 2004)? Why, instead, as presented in this work, the specific 
elimination of B-RAF leads to a reduced lung tumor growth? It is conceivable that 
the BAY 43-9006 inhibitor treatment did not block or even did induce B-RAF/C-
RAF BxB heterodimerization and therefore had no effects on the mitogenic signal 
intensity (Kramer, Gotz et al. 2004). In the present work instead, the complete 
ablation of the B-RAF protein renders RAFs heterodimerization not possible. 
Indeed, C-RAF BxB lung tumors lacking B-RAF showed a reduced intensity in 
mitogenic signal. 
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5. Materials and Methods  
5.1 Materials 
5.1.1 Instruments 
100/40/20 µm cell strainer 
Supply 
Cell culture hood 
Cell culture incubator 
Cryo microtome 
Developing machine 
Electrophoresis power supply 
Electrophoresis unit, small 
Fine scale 
Fluroscence Microscope (CCD) 
Glass coverslip 
Heat block 
Homogenizer 
Horizontal electrophoresis gel 
Incubator (37 °C) 
Inverted microscope 
Laser microdissection microscope 
Mini centrifuge 
Mega centrifuge 
Microlumat 
Microscope Slides, Super Frost® Plus 
Microtome (rotating/sliding) 
Paraffin embedding machine 
pH meter 
Roto-Gene 2000 
 
BD Falcon 
Manufacturer 
Heraeus Instrument 
Heraeus Instrument 
Leica 
Agfa 
Bio-Rad 
Bio-Rad Mini-Protean II 
Scaltec SBC 21 
Leica (Hamamatsu Orca) 
Leica 
Liebisch, Type 2099-DA 
Ultra-Turrax® 
PEQLAB 
Heraeus B 6200 
Olympus 
Leica 
Eppendorf; Biofuge 15, Heraeus 
J-6B, Beckman; Megafuge 1.0 R 
EG&G, Berthold 
Menzel-Gläzer  
Leitz Wetzlar 
Leica 
Microprocessor, WTW 
Corbett Research 
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Scale  
Shaker 
Sonicator 
Spectrophotometer 
Thermocycler 
Vortex 
Water bath 
 BP2100S, BP310S, Sartorius 
New Brunswick Scientific 
Sono Plus HD 70 
Ultraspec 3000, Pharmacia Bio. 
PE9600, Perkin Elmer ; T3, B.M. 
Scientific Industries Genie-2 
GFL 1083, Amersham-Buchler 
 
 
 
 
 
 
5.1.2 Disposable materials 
Cell culture dish (6- well) 
Supply 
Cell culture dish (12- well) 
Cell culture dish (24- well) 
Cell culture dish (96- well) 
Cell culture dish (6 cm) 
Cell culture dish (10 cm) 
Cell strainer (100 µm) 
Cell strainer (40 µm) 
Conical tubes (15 ml) 
Conical tubes (50 ml) 
Cover slips 
Embedding cassettes 
Fast Optical 96-Well Reaction Plate  
Object slides SuperFrost 
Optical Adesive Film 
Thermo-strip (0,2 ml) 
Whatman paper 
X-ray film 
 
Nunc Brand Products 
Manufacturer 
Nunc Brand Products 
Nunc Brand Products 
Nunc Brand Products 
Corning 
Corning 
Falcon 
Falcon 
Falcon 
Falcon 
Menzel-Gläser 
Simport 
Applied Biosystems 
Thermo Scientific 
Applied Biosystems 
Thermo Scientific 
Protran 
Fujifilm 
 
5.1.3 Chemicals 
Supply  Manufacturer 
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1 kb and 100 bp DNA ladder  Fermentas 
Acrylamide (30%)/Bisacrylamide (0.8%)  Roth 
Adenosin-5’Triphosphate (ATP)  Sigma 
Agarose, ultra pure  Roth 
Ammonium peroxydisulfate (APS)  Sigma 
Ampicillin  Sigma 
Bacto-Agar  Roth 
BCP  Molecular Research Center Inc. 
Bovine serum albumin (BSA)  Sigma 
Bromodeoxyuridine (BrdU)  Sigma 
Bromophenolblue  Sigma 
β-Mercaptoethanol  Roth 
Chloroform  Roth 
Diaminobenzidine (DAB)  Sigma 
DAPI  Sigma 
Diethyl pyrocarbonate (DEPC)  Merck 
Dimethylsulfoxide (DMSO)  Sigma 
Dithiothreitol (DTT)  Sigma 
DNase I (for type II cell isolation)  Sigma 
dNTPs   MBI 
Doxycycline  Sigma 
ECL-System  Amersham 
EDTA   Sigma 
Entellan  Merck 
Eosin  Merck 
Ethanol  Roth 
Ethidiumbromide  Invitrogen 
Formaldehyde  Roth 
Glycerol  Sigma 
Guanidine thiocyanate  Roth 
Haematoxylin  Merck 
HEPES  Roth 
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Hydrochloride (HCl)  Roth 
  Hydrogen Peroxide (30 %)  A. Hartenstein 
IGEPAL (NP-40)  Sigma 
Isopropanol  Merck 
Ketamin (10%)  Bela-pharm 
SeaPlaque agarose (LMP)  Lonza 
Magnesiumchloride  Sigma 
Methanol  A. Hartenstein 
Mowiol  Calbiochem 
Paraffin wax (Histosec Pastillen)  Merck 
Paraformaldehyde (PFA)  Sigma 
Phenol  Roth 
Phenol:Chloroform:Isoamylacohol  Roth 
Phenol/Chloroform (TE saturated)  Roth 
Ponceau S  Sigma 
Protein ladder, BenchMarkTM  Invitrogen, MBI 
Rnase-free water  Fermentas 
Rompun (2%)  Bayer 
SDS ultra pure  Roth 
Serum (goat)  Chemicon 
Serum (rabbit)  Chemicon 
Serum (donkey)  Chemicon 
Sodium citrate  Merck 
Sodium Chloride 
Sucrose 
 Roth 
Fluka 
TEMED  Roth 
Cryomatrix (OCT)  Thermo Scientific 
Trizol Reagent  Invitrogen 
Triton-X100 
Tween 20 
 Sigma 
Sigma 
Xylen  J. T. Baker 
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5.1.4 Antibodies 
5.1.4.1 Primary antibodies 
Antibody Catalog  Nr. Manufacturer 
anti-actin (I19) sc-1616-R Santa Cruz 
anti-Aquaporin 5 (rabbit) AQP-005 Alomone Labs 
anti-B-RAF (H145) rabbit sc-9002 Santa Cruz 
anti-B-RAF (C19) rabbit sc-166 Santa Cruz 
anti-ß-catenin (mouse) 610154 BD Transduction Lab 
anti ß-catenin (rabbit) 06-734 Upstate 
anti-CCSP (Goat) sc-9772 Santa Cruz 
anti-CD3 (rabbit) SP-7 Lab Vision 
anti-CD45 (rat) 553076 Pharmingen 
anti-CD45 (rat) 550539 Pharmingen 
anti-CD16/CD32 (Rat) 553142 Santa Cruz 
anti-cleaved caspase 3 (rabbit) 9664 Cell Signaling 
anti-C-RAF (C12) rabbit sc-133 Zymed Lab 
anti-C-RAF (E10) mouse sc-7267 Santa Cruz 
anti cow cytokeratin (rabbit) Z0622 DAKO 
anti-E-cadherin (rabbit) 3195 Cell Signaling 
anti-ERK 1/2 (rabbit) 4695 Cell Signaling 
anti-F4/80 (rat) ab6640 Abcam 
anti-Ki67 (VPK452) MM1 Vector laboratories 
anti-p120ctn (6H11) (mouse) sc-23873 Santa Cruz 
anti-Pax5 (mouse) 610863 BD Transduction Lab 
anti-phospho-ERK (rabbit) 4376 Cell Signaling 
anti-phospho H3 (S10) (rabbit) 9701 Cell Signaling 
anti-phospho-Stat3 (rabbit) D3A7 Cell Signaling 
anti-pro-SPC (rabbit)  Gift from J. Whitsett 
anti-pro-SPC (rabbit) AB 3786 Chemicon 
anti-Stat3 (rabbit) 124H6 Cell Signaling 
anti-Vimentin (C20) (rabbit) sc-7557 Santa Cruz 
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anti-Vimentin (rabbit) 3932 Cell Signaling 
anti-TTF-1 (Rat) 8G7G3/1 Imgenex 
 
5.1.4.2 Secondary antibodies 
Antibody Catalog  Nr. Manufacturer 
anti-Mouse IgG HRP conjugated NA931 V Amersham 
anti-Rabbit IgG HRP conjugated NA934 Amersham 
anti-Rat IgG HRP conjugated NA935 Amersham 
anti-cow biotinylated (Rabbit) Z0622 Dako 
anti-goat biotinylated (Rabbit) E0466 Dako 
anti-mouse biotinylated (Rabbit) E0354 Dako 
anti-mouse biotinylated (Goat) EO433 Dako 
anti-rabbit biotinylated (Goat) EO32 Dako 
 
5.1.5 Plasmids 
  
Vector Source 
SpC-B-RAF V600E Rudolf Götz 
SpC/SV40 polyA Jeffrey A. Whitsett 
 
5.1.6 Oligonucleotides 
Mouse genotyping primers 
 
Transgene 
 
 
Oligo Sequences 
 
Annealing 
T. 
 
SpC-B-RAF 
V600E 
S     5’- GGA GGA GGT GTG GAA TAT CAA AC – 3´ 
AS  5´- CCA ACA CTT CCA CAT GCA ATT C – 3´ 
 
60°C 
 
 
SpC-C-RAF 
S      5´- AAA GAC TCA ATG CAT GCC ACG – 3´ 
AS   5´- GCT GGT GTT CAT GCA CTG CAG – 3´ 
 
60°C 
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BXB 23  
RAG1 
RAG4  5´- AGA CAC AAC GGC TTG CAA CAC AG – 3´ 
RAG5  5´- TGC CGA GAA AGT CCT TCT GCC AG – 3´ 
RAG6  5´- GTG GAA TGA GTG CGA GGC CAG A – 3´ 
63°C 
 
SpC-rtTA 
S    5´- CTC CAG GAA CCC ACT CTC TG – 3´ 
AS  5´- TCC TGG CTG TAG AGT CCC TG – 3´ 
 
60°C 
 
 
Tet-O Cre 
S     5´- GAG GAG GAT GAG GGT GTC TAT AGG T – 
3´ 
AS   5´- GTG ATC AGC TCC AGG TTT GAC TT – 3´ 
 
60°C 
 
B-RAF 
floxed allel 
S     5´- TGT AGC CTC GGC TGT GGA ACT C – 3´ 
AS   5´- GAG ACC AAA CCA AGG ACC TCT G – 3´ 
60°C 
B-RAF 
wt allel 
S     5´- TGT AGC CTC GGC TGT GGA ACT C – 3´ 
AS  5´- GAG ACC AAA CCA AGG ACC TCT G – 3´ 
60°C 
B-RAF 
deleted allel 
S     5´- CCT GAA AGC TGC TAG TAG AAG AC – 3´ 
AS   5´- GAG ACC AAA CCA AGG ACC TCT G – 3´ 
60°C 
 
Primers for RT-PCR 
 
Gene 
 
 
Oligo Sequences 
 
Annealing 
T 
Human  
B-RAF  
S      5’- GTC ATC TTC ATC CTC AGA AG – 3´ 
AS   5´- TTC AAC ATT TTC ACT GCC AC- 3´ 
 
60°C 
 
Mouse  
B-RAF  S      5’- CAT CTT CTT CCT CAT CCT CG – 3´ 
 
60°C 
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AS   5´- TTC AAC ATT TTC ACT GCC AC- 3´ 
Mouse 
E-cadherin 
S      5’- GCTGGACCGAGAGAGTTA – 3´ 
AS   5´- TCGTTCTCCACTCTCACAT – 3´ 
60°C 
Mouse 
HPRT 
S      5’- TCAGTCAACGGGGGACATAAA – 3´ 
AS   5´-  GGGGCTGTACTGCTTAACCAG – 3´ 
60°C 
Mouse  
Vimentin 
S       5´- GTGCGCCAGCAGTATGAAAG – 3´ 
AS     5´- GCATCGTTGTTCCGGTTGG -3´ 
60°C 
ß actin 
S       5’- GTCGTACCACAGGCATTGTGATGG – 3´ 
AS      5’- GCAATGCCTGGGTACATGGTGG – 3´ 
60°C 
 
Primers for amplification of genomic DNA 
 
Gene 
 
 
Oligo Sequences 
 
Annealing 
T 
EGFR 
 exon 19 
S       5’- CCAGCTCACAAGGCAACATG – 3´ 
AS     5’- CCCACGTCCCTATAAGCAGA – 3´ 
55°C 
EGFR 
 exon 20 
S       5’- AAGGGATATGCGTGCCTCTC – 3´ 
AS     5’- GGGTACTTCAGTGGACAGAC – 3´ 
55°C 
EGFR 
 exon 21 
S       5’- ACCCTGTGTTCAGGTGCATG – 3´ 
AS     5’- CTGGGCTGTCAGGAAAATGC – 3´ 
55°C 
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K-Ras 
exon 1 
S       5’- ATGACTGAGTATAAACTTGT – 3´ 
AS     5’- TCGTACTCATCCTCAAAGTG – 3´ 
55°C 
K-Ras 
exon 2 
S  5’- TACAGGAAACAAGTAGTAATTGATGGAGAA – 3´ 
AS  5’- ATAATGGTGAATATCTTCAAATGATTTAGT – 3´ 
50°C 
p19ARF 
exon 1 
S       5’- TTGTCACAGTGAGGCCGCCG – 3´ 
AS     5’- GCACCTGTGCGTGCAGCTTC – 3´ 
54°C 
p16INK4a 
exon 1 
S       5’- GCGAACTCGAGGAGAGCCAT – 3´ 
AS     5’- TTACCCGACTGCAGATGGGACAC – 3´ 
53°C 
p16INK4a 
exon 2 
S       5’- CTGGCCGTGATCCCTCTACT – 3´ 
AS     5’- GAGTGTCAGAAGCTTTTGGACCAA – 3´ 
53°C 
p16INK4a 
exon 3 
S       5’- CTGGCACCTAGGACAGCTTTATA – 3´ 
AS     5’- GAAAAAGGCGGGCTGAGGCC – 3´ 
53°C 
p53 
exon 5 
S       5’- GCTTGTCCCCGACCTCCGTT – 3´ 
AS     5’- GGCTGCCAGTCCTAACCCCAC – 3´ 
55°C 
p53 
exon 7 
S       5’- CCACAGGTCTCCCCAAGG – 3´ 
AS     5’- TGGCAAGTGGCTCCTGAC – 3´ 
55°C 
p53 
exon 8 
S       5’- TCTTACTGCCTTGTGCTGGTCC – 3´ 
AS     5’- AGGCTCCTCCGCCTCCTT – 3´ 
55°C 
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LKB1 
exon 1 
S       5’- GCTCCCGAAGGGGACGAGGA – 3´ 
AS     5’- AGGAAGGGCTGCCCAAGGAG – 3´ 
50°C 
LKB1 
exon 2 
S       5’- CAGCAGGCAGGGTCAGCTAA – 3´ 
AS     5’- CCAGCCCACTCCACCCACAG – 3´ 
50°C 
LKB1 
exon 6 
S       5’- ACCCTGTAGCGGGGGG – 3´ 
AS     5’- CCTCCCATCCGGACAA – 3´ 
50°C 
 
5.1.7 Enzymes 
Enzyme Catalog  Nr. Manufacturer 
Collagenase C0130-100MG Sigma Aldrich 
Dispase 17105-041 Gibco 
DnaseI (for cloning) EN0521 Fermentas 
DnaseI 
(for type type II cell isolation) 
04 716 728 001 Roche 
Klenow fragment EP0051 Fermentas 
Proteinase K (for tail lysate) 7528.3 Roth 
Proteinase K (for histology) P5568-1ML Sigma Aldrich 
Shrimp Alkaline Phosphatase EF0511 Fermentas 
Taq-Polymerase GC-002-0500 Genecraft 
T4 DNA ligase EL0011 Fermentas 
 
5.1.8 Kits 
Product Catalog  Nr. Manufacturer 
Dead End Fluorometric TUNEL Kit TB235 Promega 
First Strand cDNA Synthesis Kit K1612 Fermantas 
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Pierce ECL Western Blotting 
Substrate 
32106 Thermo Scientific 
Pierce® BCA Protein Assay Kit 23227 Thermo Scientific 
QIAGEN Plasmid Maxi Kit 12163 Qiagen 
QIAprep Spin Miniprep Kit 27104 Qiagen 
QIAquick PCR purification kit 28104 Qiagen 
QIAquick Gel Extraction Kit 28706 Qiagen 
REDTaq® ReadyMix™ PCR 
Reaction Mix 
2523-100RXN Sigma-Adrich 
Trichrome stain (Masson) HT15 Sigma-Adrich 
Vectastain® ABC-peroxidase kit PK6100 Vector laboratories 
 
5.1.9 Bacterial strains and Mouse lines 
Bacterial strains 
Bacterial strains Source 
DH5α New England Biolabs 
 
Mouse lines 
Mouse lines Source 
floxed B-RAF MSZ 
LC1 (Tet-o-Cre) Gift from Hermann Bujard 
Rag1 -/- Jackson Laboratory 
SpC-B-RAF V600E This work 
SpC-C-RAF BxB23 MSZ 
SpC-rtTA Gift from Jeffrey A. Whitsett 
 
Materials and Methods 
 
82 
 
5.2 Methods 
5.2.1 Bacterial manipulation 
5.2.1.1 Transformation of competent bacteria 
Competent E. Coli DH5α strain was transformed with plasmid DNA using the 
Heat Shock transformation protocol. Briefly, 50 µl of competent bacteria were 
mixed with ~100 ng plasmid DNA and incubated for 15 minutes on ice. The mix 
was placed for 45 seconds at 42°C and subsequently put on ice for 2 minutes. 
After adding 200 µl of LB medium without antibiotics the bacteria were incubated 
for 1 hour at 37° C. 100 µl of the culture were spread on LB agar plate supplied 
with required antibiotics and placed overnight at 37°C.      
  
LB-Medium  
1.0 % Trypton 
0.5 % Yeast Extract 
1.0 % NaCl 
pH 7.2 
 
For preparation of LB-plates, 1.5 % of agar was added.  
Antibiotic concentrations were 100 μg/ml for Ampicillin and 70 μg/ml for 
Kanamycin.  
5.2.1.2 Purification of plasmid DNA 
For mini or maxi plasmid DNA purification, a single colony of previously 
transformed E coli was inoculated in 5 or 100 ml LB medium, respectively, 
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supplemented with required antibiotics and grown overnight at 37°C, 200 rpm in 
an shaking incubator. DNA isolation was achieved using QIAGEN Plasmid Kits 
following the manufacturer’s instructions.  
5.2.2 DNA analysis 
5.2.2.1 Measurement of DNA concentration 
DNA concentration was determined by measuring the absorbance at 260 nm 
using the NanoDrop ND 1000 spectrophotometer (Thermo Scientific). The DNA 
purity was controlled by the ratio of absorbance values at 260 nm and 280 nm 
(A260/A280) which should be between 1.8 and 2. If the ratio A260/A280 is lower than 
1.8 indicates protein contamination in the sample.  
5.2.2.2 Enzymatic digestion of DNA with restriction enzymes 
DNA molecules were digested according to the following protocol: 1-3 µg DNA, 
10 unit of enzyme, 1X enzyme buffer and water up to 10 or 20 µl of final volume. 
Reactions were incubated at 37 °C for 1-2 hours. Enzyme´s activity was normally 
stopped by thermal inactivation according to the instructions of the supplier.     
5.2.2.3 Ligation of DNA fragments 
Sticky-end ligation was carried out by mixing, in a total volume of 20 µl, vector 
and insert (in a molar ratio of 1:3), 2 µl T4 DNA ligase buffer and 1 µl T4 DNA 
ligase (Fermentas). The reaction was incubated for 1 h at 22°C. T4 DNA ligase 
was inactivated by heating at 65°C for 15 minutes.  
Blunt-end ligation was essentially carried out as previously described except that 
2 µl of PEG 50% solution were added to the ligation mix.   
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5.2.2.4 Polymerase-Chain-Reaction (PCR)  
Amplification of DNA fragments was achieved via PCR method in automated 
thermo cyclers (Biometra). Usually, the reaction was carried out in a 30 µl mix 
which comprised 2 µl DNA sample, 0.5 µl (10 pmol) primers forward and reverse, 
3 µl 2 mM dNTPs mix (Fermentas), 3 µl 10X Taq polymerase buffer (Fermentas) 
and 0.2 µl Taq polymerase (Supplied by the Max Planck Institute of 
Biochemistry).  
In some cases the REDTaq ReadyMix PCR Reaction with MgCl2 (Sigma, R2523) 
was used according to the manufacturer´s instructions.  
 
The following PCR cycling protocol was adjusted to each specific application: 
 
3 min 95°C     (initial denaturation) 
30 cycles: 
1 min 95°C     (denaturation) 
1 min T°C       (appropriate annealing temperature according to the primers) 
1-3 min 72°C  (extension) 
5 min 72°C     (final extension) 
4°C end 
 
PCR products were resolved on 1-3 % agarose gel or digested with restriction 
enzymes for other applications.  
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5.2.2.5 Agarose gel electrophoresis 
Agarose gels were prepared by mixing agarose in TAE buffer to a final 
concentration of 0.8-3 %. Each solution was boiled in a microwave oven until the 
agarose was completely dissolved. Ethidium bromide was added (0.5 μg/ml final 
concentration) and the solution was poured in a horizontal chamber. After the gel 
has become solid DNA samples were loaded onto the gel with an appropriate 
amount of 6x gel loading buffer and electrophoresis was performed in TAE at 120 
V for 25-35 minutes. DNA fragments were visualized under UV light and 
photographs were taken. 
 
TAE buffer: 
40 mM Tris/Acetate pH 8.0  
1 mM EDTA 
5.2.2.6 DNA fragment extraction from agarose gel 
DNA fragments separated by gel electrophoresis were extracted under UV light 
with a scalpel. Agarose was dissolved and the DNA was isolated using the 
QIAquick Gel Extraction Kit (Qiagen) according to the supplier´s instructions. 
5.2.2.7 DNA sequencing 
DNA sequencing was performed in an ABI 3730 sequencer. 10 µl sequencing 
mix included: ~ 300ng plasmid DNA or ~100 ng PCR product, 10 pmol primers, 
1.5 µl BigDye Mix 3.1 (ABI) and 1 µl 5x-buffer. Sequences were visualized with 
Chromas Lite program. 
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5.2.3 RNA analysis 
5.2.3.1 RNA isolation from cells and tissues 
RNA isolation from cells or tissues was performed using TRIzol Reagent 
(Invitrogen) according to the manufacturer’s instructions. Briefly, ~100 mg frozen 
tissue was homogenized in 1 ml TRIzol solution with an Ultra-Turrax (IKA) in cold 
environment. Phase separation was carried out by adding either 100 µl of BCP 
reagent (MCP) or 200 µl Chloroform. Probes were vortexed for 15 seconds, 
incubated at room temperature for 2-5 minutes and then centrifuged for 5 minutes 
at full speed at 4°C. RNA contained in the upper aqueous phase was precipitated 
by adding 500 µl isopropanol and centrifuged for 10 min at full speed at 4° C. 
Pellet containing RNA was washed with 70 % ethanol, air dried and dissolved in 
DEPC water.        
5.2.3.2 Measurement of RNA concentration 
RNA concentration was determined by measuring the absorbance at 260 nm 
using the NanoDrop ND 1000 spectrophotometer (Thermo Scientific). The RNA 
quality was estimated by the ratio of absorbance values at 260 nm and 280 nm 
(A260/A280). Only RNA with a ratio between 1.8 and 2 was used for further 
experiments.    
5.2.3.3 cDNA synthesis 
cDNA was made from total RNA by using the First Strand cDNA Synthesis Kit 
(Fermentas) according to the manufacturer´s instructions. To avoid genomic DNA 
contaminations, ~1 µg of total RNA was incubated for 30 minutes at 37°C with 1 
µl RNase-free DNase I (Fermentas) in presence of 1 µl DNase I buffer 
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(Fermentas) in 10 µl total volume. Dnase I was inactivated by adding 1 µl EDTA 
and incubating for 10 minutes at 65°C. cDNA synthesis was carried out by 
directly using Dnase I treated RNA and oligo d(T) primers (First Strand cDNA 
Synthesis Kit, Fermentas).  
5.2.3.4 Real-Time PCR 
Quantitative Real-Time PCRs were performed in a Rotor-Gene 2000 detection 
system (Corbett Research). Each 20 µl PCR mix included 2 µl pre-diluted cDNA 
(1:10 or 1:20), 10 µl SYBR green PCR master mix (F-410S/L, DyNAmo HS 
SYBR Green qPCR Kit), 0.4 µl dye ROX and 10 pmol forward and reverse 
primers, respectively. The PCR program was as follows: 5 minutes Taq activation 
and initial denaturation at 95° C followed by 40 cycles with 15 seconds of 
denaturation at 95° C, 15 seconds annealing at 61° C and 15 seconds elongation 
at 72°C. Primers specificity was evaluated by melt curve analysis. To calculate 
the transcript levels of the genes of interest, the amplification efficiency was 
raised to the power of the threshold cycle (Ct-value). The Ct-value is defined as 
the number of cycles that are necessary for the fluorescence signal to exceed the 
background levels. In each sample all values were normalized to housekeeping 
genes such as β-actin or HPRT in order to obtain relative amount of target 
mRNA. All assays were performed in duplicate or triplicate.          
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5.2.4 Protein analysis 
5.2.4.1 Preparation of whole protein lysates from cells and tissues 
Tissues were lysed in ice-cold RIPA buffer with protease and 88hosphor88e88 
inhibitor cocktails (Roche) using an Ultra-Turrax (IKA) homogenizer in a cold 
environment. After centrifuging for 10 minutes at full speed at 4°C, supernatant 
containing proteins was transferred into a new tube to measure the protein 
concentration. 
 
RIPA buffer: 
50 mM Tris-HCl, pH 8.0  
150 mM NaCl  
0.1 % SDS  
0.5 % deoxycholate [DOC] 
 1 % Nonidet P-40 
5.2.4.2 Measurement of protein concentration 
Protein concentration was measured by using the BCA protein assay kit (#23225, 
Thermo Scientific) according to the supplier’s instructions and using Bovine 
Serum Albumin (BSA) as standard control. 20-30 µg proteins were denatured by 
mixing with 3x laemmli buffer supplied with ß-Mercaptoethanol and heated for 10 
minutes at 95 °C. Protein lysates were stored at -20°C prior to SDS-PAGE and 
immunoblot analysis.      
 
3X laemmli buffer: 
100 mM Tris/HCl pH 6.8 
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3 % SDS 
45 % Glycerol 
0.01 % Bromphenol blue 
7.5 % ß-Mercaptoethanol 
5.2.4.3 SDS-PAGE 
SDS-PAGE was carried out using the Mini-PROTEAN Tetra Cell system from 
Bio-Rad (Catalog Number: 165-8000). Glass cassettes and electrophoresis 
modules were assembled according to the manufacturer’s instructions. A 
resolving gel of 8 – 15 % acrylamide was prepared and poured between the two 
glass cassettes, leaving a space of about 1 cm for the staking gel. Isoparopanol 
was added on top of the solution. After the gel was polymerized the isopropanol 
was removed. A staking gel of 5 % acrylamide was prepared and poured on the 
resolving gel. Immediately, a comb with either 10 or 15 wells was inserted and 
the gel was allowed to polymerize. After polymerization the comb was removed 
and the wells were rinsed with water. The gel was placed in the electrophoresis 
module and the tank was filled with 1X SDS-PAGE running buffer. Protein 
samples were incubated at 95°C for 5 minutes and shortly centrifuged. Protein 
marker (6.5 µl/well) and protein samples (20 µl/well) were loaded on gel and the 
electrophoresis was run at 110 V by using a powerpac 300 power supply (Bio-
Rad) for about 1.5 h. After electrophoresis the gel was removed from the glas 
cassettes and subjected to western blotting. 
 
Resolving gel: 
Tris 1M pH 8.8                               1.25 ml 
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10 % SDS                                       50 µl 
10 % APC                                       50 µl  
30 % Acrylamide/Bisacrylamide     1.33-2.5 ml 
Temed                                            3 µl 
H2O                                                up to 5 ml 
 
Stacking gel:             
Tris 1M pH 6.8                               0.3125 ml 
10 % SDS                                       25 µl 
10 % APC                                       25 µl  
30 % Acrylamide/Bisacrylamide     0.425 ml 
Temed                                            2.5 µl 
H2O                                               up to 2.5 ml 
 
10X SDS-PAGE buffer: 
25 mM Tris/HCl pH 7.5 
200 mM Glycine 
0.1 % SDS 
5.2.4.4 Immunoblotting 
Western blot was carried out by using the Mini Trans-Blot Electrophoretic 
Transfer Cell system from BIO-RAD (Catalog number 170-3930) according to the 
manufacturer´s instructions. Briefly, the gel sandwich was prepared by placing in 
the following order: fiber pad, two Whatman filters, gel, nitrocellulose membrane, 
two Whatman filters and fiber pad. The sandwich gel was placed in the blotting 
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cassette and subsequently deposited in the blotting tank with a cold pack. The 
blotting tank was filled with SD-transblot buffer and run at 400 mA for 1 h. After 
blotting, the nitrocellulose membrane was incubated for 1 h at room temperature 
with 5% milk in NETG to block unspecific binding of the antibody. Primary 
antibodies were diluted in NETG and incubated overnight at 4°C. After 
incubation, the nitrocellulose membrane was washed 3x for 10 minutes with 
NETG and subjected to 91hosphor91e-conjugated secondary antibody (1:5000 
diluted in NETG) for 1 h at room temperature. The nitrocellulose membrane was 
then washed 3x for 10 minutes with NETG and probed with the ECL 
chemiluminescence reaction (Thermo Scientific) according to the supplier´s 
instructions. Proteins were visualized by exposing the nitrocellulose membrane to 
an X-ray film that was subsequently developed in a PROTEC x-ray processor.   
 
SD-transblot buffer: 
50 mM Tris/HCl pH 7.5 
40 mM Glycine 
20 % Methanol 
0.004 % SDS  
 
1x NETG: 
50 mM Tris/HCl pH 7.4 
5 mM EDTA 
0.05 % Triton X-100 
150 mM NaCl 
0.25 % Gelatine     
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5.2.4.5 Stripping of membrane  
Stripping was carried out by incubating the nitrocellulose membrane with 
stripping buffer for 30 minutes at 54°C in a shaking incubator. The membrane 
was then washed 3x for 10 minutes with NETG, blocked with 5% milk in NETG 
for 1 h at room temperature and subsequently re-probed with other primary 
antibody as described in 5.2.4.4.   
 
Stripping buffer:  
62.5 mM Tris/HCl pH 6.8 
2% SDS 
100 mM β-Mercaptoethanol  
 
5.2.5 Mouse work 
All animal experiments were performed according to the regulations of the 
Bavarian State authorities. Mice were housed in air-filtered units with a 12-hour 
dark/light circle and with the access to food and water ab libitum. 
5.2.5.1 Generation of transgenic mice 
For generation of transgenic mice constitutively expressing B-RAF V600E in lung 
alveolar type II cells, the SpC-B-RAF V600E expression cassette (6,2 Kb) was 
resolved in a low melting agarose gel after digestion with Hind III restriction 
enzyme. The purified fragment was then injected into the pronucleus of fertilized 
eggs of FVB/n mice. Three positive founders that showed germ line transmission 
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were obtained. All founders were backcrossed to C57Bl/6 for more than six 
generations before experiments. 
5.2.5.2 Breeding of mice 
Mating was started when female and male mice were at least 4 and 6 weeks old, 
respectively. Often two females were bred together with one male. Matings were 
stopped by separating males from the pregnant female after ~2 weeks. Pups 
were separated from the mother at the age of 3-4 weeks, at this point each 
mouse was marked by an earmark and a tail biopsy was taken for genotyping.           
5.2.5.3 Genotyping of mice 
Tails were lysed overnight at 54°C in 190 µl lysis buffer and 10 µl proteinase K 
(0,4 mg/ml). Tail lysates were centrifuged at full speed for 10 minutes, diluted 
1:10 or 1:40 with sterile water and used as template for PCR reaction as 
described in 5.2.2.4 using the genotyping primers reported in 5.1.6. In some 
cases a preliminary step of DNA isolation followed by PCR detection was 
necessary. DNA isolation was carried out by adding to tail lysates 250 µl lysis 
buffer and 250 µl of saturated NaCl (~5M NaCl). The mixture was mixed by 
inversion ~10 times, incubated 5 minutes at room temperature and centrifuged at 
full speed for 10 minutes. The supernatant was transferred into new 1.5 ml tube 
and DNA precipitation done by adding 600 µl isopropanol. The sample was 
mixed by inversion ~10 times, incubated 5 minutes at room temperature and 
centrifuged at full speed for 10 minutes. Supernatant was discarded and the DNA 
containing pellet was washed by adding 1 ml of 100% ethanol and centrifuging at 
full speed for 5 minutes. Finally, pellet was air-dried for 10-15 minutes at room 
temperature and resuspended with 50-100 µl sterile water. This DNA solution 
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was diluted 1:10 or 1:40 with sterile water and used as template for PCR reaction 
as described in 5.2.2.4 using the genotyping primers reported in 5.1.6.   
 
Tail lysis buffer 
50 mM EDTA 
50 mM Tris-HCl  
0.5% SDS 
pH 8.0    
5.2.5.4 Sacrification of mice 
Mice were euthanized with a lethal intraperitoneal injection of Ketamin and 
Rompun in PBS. After the loss of righting reflex, mice were perfused by intra-
cardiac injection of PBS and organs were isolated.  
For embryos isolation, pregnant females were sacrificed by cervical dislocation. 
The uterus of the mice was dissected and embryos were isolated from the yolk 
sac.  
5.2.5.5 Lung type II cells isolation 
At least 24 hours before cell isolation, 10 cm dishes were coated with 6 ml PBS 
containing 42 µg anti-mouse CD45 (84 µl) (Pharmingen #553076) and 16 µg anti-
mouse CD32 (41 µl) (Pharmingen #553142).    
For lung type II cells isolation mice were euthanized and perfused as reported in 
5.2.5.4. After intratracheal injection of 3-5 ml dispase (2,1 U/ml) followed by 0.5-1 
ml of 1% low melting agarose, animals were covered with ice and incubated for 
~2 minutes to harden the agarose. Lungs were dissected, placed in 15 ml tubes 
containing 3 ml collagenase (1 mg/ml) and incubated for 1 hour at 37°C. Excess 
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dispase was removed from 15 ml tubes and lungs were placed in 60 mm dishes 
containing 7 ml DMEM/HEPES and 100 U/ml DNaseI. By use of forceps, lungs 
were squeezed “like a tea bag” (for ~5 minutes) until only connective tissue was 
visible to move cells in suspension. Cell suspensions were filtered two times 
through a 100 µm cell strainer (Falcon), one time through a 40 µm cell strainer 
(Falcon) and placed in 50 ml tubes. After centrifugation at 130 g for 8 minutes at 
4°C cell pellets were resuspended in 10 ml DMEM/HEPES containing 10% FBS. 
Antibody solution was discarded from coated plates and 10 cm dishes were 
gently washed with DMEM/HEPES. Cell suspensions were put on plates and 
incubated for 2 h at 37°C to allow the attachment of immune cells. Cell 
suspensions were collected from plates, placed in 50 ml tubes and centrifuged at 
130 g for 8 minutes at 4°C. After gently removing the supernatant cell pellets 
were snap-frozen in liquid nitrogen.    
 
5.2.6 Histological techniques 
5.2.6.1 Paraffin-embedding and sectioning of tissue 
Animals were sacrificed and lungs were fixed under 25 cm water pressure with 4 
% buffered paraformaldehyde and paraffin embedded. Tissue was placed in 
proper embedding cassettes and paraffin embedding was carried out as follow. 
Paraffinization requires essentially three steps: dehydration, clearing and 
embedding. Dehydration process was achieved by passing the tissue through a 
series of increasing alcohol concentrations, the detailed steps were: 1 hour in 
50% ethanol, 1 hour in 70% ethanol, 1 hour in 80% ethanol, 1 hour in 90% 
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ethanol and 2 times for 1 hour in 100% ethanol. Clearing refers to the use of an 
intermediate fluid that is miscible with ethanol and paraffin since these two 
substances are immiscible. This step was carried out by passing the tissue, twice 
for 30 minutes, through a 1:1 mixture of xylol and ethanol and subsequently 2 
times for 30 minutes in xylol only. All these steps were performed at room 
temperature in an automated tissue processor (Shandon Citadel 2000). For 
embedding procedure the tissue was transferred into melted paraffin and 
incubated for 1 hour at 65°C and then in fresh paraffin for 2 hours or overnight at 
65°C. Finally, the tissue was placed into an embedding mold and melted paraffin 
was poured into the mold to form a block. After cooling down the blocks were 
ready for sectioning. Tissue blocks were sectioned in 6 µm sections by using a 
manual rotary microtome (Leica RM2235).  
Embedding of mouse embryos was essentially carried out as already described 
except that chloroform was used instead of xylol and that the last step of paraffin 
incubation was prolonged to 5-7 days. Embryos tissue blocks were sectioned in 
10 µm microsections.     
 
4% PFA in PBS 
Place 37 g PFA in 850 ml H2O 
Add 2-3 drops of 1 N NaOH 
Heat to 60°C and mix until the PFA is dissolved. 
Add 100 ml 10X PBS and bring pH to 7.4. 
Bring final volume to 1l with H2O. 
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5.2.6.2 Optimal Cutting Temperature (O.C.T.)-embedding and 
cryosectioning of tissue 
Freshly isolated tissue was fixed in 4% PFA at 4°C for 4 hours. After washing two 
times for 10 minutes in PBS, the tissue was transferred into 15% sucrose in PBS 
and incubated for 4 hours at 4°C. Subsequently, it was placed overnight at 4°C in 
30% sucrose in PBS. Finally, the tissue was embedded on dry ice in OCT 
(Shandon Crymatrix) and stored at -80°C. Blocks were sectioned into 6-10 µm 
microsections that were either directly used for experiments or stored at -80°C.     
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5.2.6.3 Hematoxilin and Eosin staining of tissue (H & E staining) 
 H & E staining of paraffin embedded sections was carried out following the 
protocol reported below:  
Solution Time 
Xylol-I 10 minutes 
Xylol-II 10 minutes 
100% alcohol-I 5 seconds 
100% alcohol-II 5 seconds 
100% alcohol-III 5 seconds 
700% alcohol 10 minutes 
Water 5 minutes 
Haematoxylin 2 minutes 
Tape water 5 minutes 
Eosin 5 seconds 
Water 5 seconds 
70% alcohol 5 seconds 
100% alcohol-I 5 seconds 
100% alcohol-II 5 seconds 
100% alcohol-III 10 minutes 
100% alcohol-III 10 minutes 
Xylol-I 10 minutes 
Xylol-II 10 minutes 
 
After the last incubation in xylol the tissue sections were mounted in Entellan 
(Merck). 
5.2.6.4 Immunostaining of tissue 
For immunostaining of tissue, paraffin embedded tissue sections were 
deparaffinised and rehydrated as reported in the H&E staining protocol. Applied 
Deparaffinization 
and 
reydration 
Dehydration 
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antigen-retrieval methods were either heat- or enzymatic-mediated according to 
the antibodies that were used. In the heat-mediated antigen retrieval, tissue 
sections were placed in a microwavable vessel containing 10 mM Citrate buffer 
(pH 6) and heated in a microwave oven for 6-20 minutes. In the enzymatic-
mediated antigen retrieval, proteinase K solution (20 μg/ml in TE buffer, pH 8) 
was pipetted onto the tissue slides and incubated for 7-20 minutes at 37°C. After 
cooling down for 30 minutes at room temperature, sections were washed with 
water and then three times for five minutes with PBS.  Endogenous peroxidase 
activity was quenched by incubating the tissue slides with 0.3-3% H2O2 in PBS or 
methanol for 30 minutes at room temperature. After washing three times for five 
minutes, unspecific binding of the antibodies was blocked by incubating the 
tissue with a blocking solution containing 3-5 % normal serum which was 
prepared from the species in which the secondary antibody is made and 0.1 % 
TritonX-100 in PBS for 1 hour at room temperature. Primary antibody was diluted 
in blocking solution, applied on tissue sections and incubated overnight at 4°C. 
After washing three times for 10 minutes, tissue sections were incubated for 90 
minutes at room temperature with biotinylated secondary antibody 
(DakoCytomation) 1:200 diluted in blocking solution. ABC reagent ((Vectastain 
Elite ABC Kit, Vector Labs) was prepared and applied to tissue sections 
according to the manufacturer´s instructions, and then developed in 
diaminobenzidine (DAB) (0.8% H2O2 in 1 ml DAB). The reaction was stopped with 
water for 5 minutes, subsequently tissue slides were counterstained with 
hematoxilin for 20 seconds, washed with tap water, dehydrated and mounted in 
Entellan (Merck) as reported in the H&E staining protocol.   
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Immunofluorescence staining was carried out essentially as previously described 
except that secondary antibody fluorochrome-conjugated, diluted (1:200) in 
blocking solution, was used. Moreover counterstaining was done by using 4’.6-
diamidino-2-phenylindole (DAPI) and by mounting with Mowiol (Roth).  
 
In the table below the antibody dilutions and antigen retrieval conditions applied 
to each immunostaining are reported:     
Article Company Dilution 
Antigen 
retrieval 
Incubation 
Aquaporin-5 Almone Labs 1:1000 Citrate buffer 6 min 
B-RAF (H145) Santa Cruz 1:250 Citrate buffer 10 min 
CCSP (T18) Santa Cruz 1:2500 Citrate buffer 12 min 
CD3 Lab Vision 1:1000 Citrate buffer 10 min 
CD45 Pharmingen 1:20 Proteinase K 
20 min at 
37°C 
cleaved 
Caspase-3 
Cell Signaling 1:200 Citrate buffer 20 min 
C-RAF (E10) Santa Cruz 1:100 Citrate buffer 10 min 
Cytokeratin Dako 1:400 Citrate buffer 10 min 
F4/80 Abcam 1:100 Proteinase K 
7 min at room 
temperature 
Ki67 
Vector 
laboratories 
1:50 Citrate buffer 15 min 
Pax5 
BD 
Transduction 
laboratories 
1:1000 Citrate buffer 6 min 
Phospho-ERK  
(Thr202/Tyr204) 
Cell Signaling 1:100 Citrate buffer 10 min 
Phospho-H3 
(Ser10) 
Cell Signaling 1:200 Citrate buffer 15 min 
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Phospho-Stat3 
(Tyr 705) 
Cell Signaling 1:100 Citrate buffer 15 min 
Pro-SPC J. Whitsett 1:2000 Citrate buffer 10 min 
Pro-SPC Chemicon 1:500 Citrate buffer 10 min 
TTF-1 Imgenex 1:100 Tris-EDTA 20 min 
Vimentin (C20) Santa Cruz 1:200 Citrate buffer 12 min 
 
10 mM Citrate buffer (pH 6): 
Stock solutions: 
Solution A = 0.1 M citrate acid solution (21.01 g citric acid, monohydrate in 1 L 
H2O) 
Solution B = 0.1 M sodium citrate (29.49 g trisodium citrate dehydrate in 1 L H2O)  
 
Working solution (pH 6): 
18 ml solution A 
82 ml solution B 
to 1 L with H2O 
 
TE buffer: 
50 nM Tris Base (pH 8.0) 
1 mM EDTA  
0.5% Triton X-100       
5.2.6.5 Immunohistopathological analysis of tissue 
For analysis of airspace enlargements lungs from wild type and transgenic mice 
were evaluated blindly by two independent examiners. Tissue samples were 
graded in the following manner: 1) Micro- and macro- scopically normal; 2) 
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Macroscopically normal, but microscopically abnormal [airspace enlargement]; 3) 
Macroscopic abnormalities [bulb formation]. 
For scoring of active caspase 3 and Ki67 immunostainings at least 10 randomly 
selected areas were counted from at least 4 mice for each time point. Collagen 
accumulation was detected by staining lung sections with Masson´s Trichrome 
stain kit (Sigma Aldrich). Lung Goblet cells hyperplasia and mucus production 
were assessed by calculating the fraction of Alcian Blue positive stain per length 
of basal membrane in 7-10 large and small bronchial airways (wild type [1-3 
months] n= 6, [4-28 months] n= 8; SpC-B-RAF V600E [1-3 months] n= 7, [4-28 
months] n= 8).  Calculation of lymphoid follicles incidence was done by analyzing 
CD45 stained lung sections under the microscope for each mouse. Macrophages 
quantification was carried out by counting the number of F4/80 positive cells in 10 
randomly selected pictures taken at 40X magnification per mouse lung section. 9 
animals for each age and genotype were used. 
Lung tumor load was determined by counting the number of tumors in 5-7 
randomly selected pictures (taken at 10x magnification) in H&E or C-RAF stained 
lung sections. For each lung, two no consecutive slides (at least ~ 100 µm apart) 
were used for quantification. At least 5 mice for each genotype and age were 
analyzed. Tumor volume (in µm3) was calculated in the same lung sections used 
to determine the tumor load by assuming a spherical form. For quantitation of 
active caspase 3, TUNEL, Ki67 and phosphoH3 immunostainings 15 randomly 
selected tumors were counted from 5 mice for each genotype. The intensity of 
the MAPK signal in tumor bearing lungs was assessed by estimating the 
percentage of tumor cells with 102hosphor-ERK nuclear staining. For each lung 
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at least 10 tumors were quantified and at least 5 mice for each genotype were 
analyzed.   
5.2.6.6 PCR-amplification of genomic DNA from paraffin section  
DNA of tumors was isolated from 6 µm H&E stained paraffin embedded lung 
sections by using a sterile scalpel. DNA was isolated after solubilisation of the 
pooled material in 30 µl of lysis buffer (10mM TrisHCl, 1 mM EDTA, 1% w/v 
Tween 20, 100µg/ml proteinase K) overnight at 37º C. Proteinase K was blocked 
by heating the samples to 95º C for 20 minutes. 1 µl of this sample was used for 
PCR amplification of genomic DNA following the protocol reported in 5.2.2.4 and 
using the oligos listed in 5.1.6 
5.2.7 Statistical analysis  
Data sets from independent experiments were pooled and the results were 
shown as means with SEM (standard error of the mean). All statistical analyses 
were performed using GraphPad Prism4 software. Log-rank analysis was used to 
compare the survival rate of different group of mice. Student’s t-test (two-tailed) 
was used to compare two groups (P<0.05 was considered significant). 
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7. Appendix 
7.1 Abbreviations 
Abbreviation Full name 
APS Ammoniumpersulfate 
ATP Adenosine-5’-triphosphate 
BCP 1-Bromo-3-Chloropropane (C3H6BrCl) 
bp Basepairs 
BSA Bovine Serum Albumin 
°C Degree Celsius 
CCSP Clara cell secretory protein 
cDNA Complementary DNA 
CO2 Carbon dioxide 
DAPI 4’,6-Diamidino-2-phenylindol 
DMEM Dulbecco’s Modified Eagle Medium 
DMSO Dimethylsulphoxide 
DNA Deoxyribonucleic acid 
dNTP (Di)Desoxynucleotide triphosphate 
DOX Doxycycline 
ECL Enhanced Chemiluminescence 
EDTA Ethylenediaminetetraacetic acid 
et al. Et alii 
FCS Fetal calf serum 
FITC Fluorescein isothiocyanate 
Floxed Flanked by loxP site 
g Gram 
GAPDH 
Glyceraldehyde-3-phosphate 
dehydrogenase 
HCl Hydrochloric acid 
H&E Hematoxylin/eosin staining 
hm Hyper methylation 
HPRT Hypoxanthine guanine phosphoribosyl 
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transferase 
Kb Kilo basepair 
kDa Kilo dalton 
ko Knock-out 
L Liter 
LOH Loss of heterozygosity 
M Month 
mA Milliampere 
mg Milligram 
min Minutes 
mM Millimolar 
NaOH Sodium hydroxide 
NP40 
Nonidet P-40  
(octyl phenoxypolyethoxylethanol) 
NSCLC Non-Small-Cell Lung Cancer 
OCT Optimal cutting temperature 
OD Optical density 
PAGE Polyacrylamide Gel Electrophoresis 
PCR Polymerase Chain Reaction 
PBS Phosphate Buffered Saline 
PFA Paraformaldehyde 
rpm Rounds per minute 
RT Room temperature 
RT-PCR 
Reverse transcriptase polymerase chain 
reaction 
rtTA Reverse tetracycline transactivator 
SCLC Small-Cell Lung Cancer 
SDS Sodium dodecylsulfate 
SP-C Surfactant Protein C 
TAE Tris-Acetate-EDTA 
TEMED N,N,N’,N’-Tetramethylethylenediamine 
tet tetracycline-regulated 
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Tet-O tetracycline operator 
Tris Tris(hydroxymethyl)aminomethane 
TRITC Tetramethylrhodamine isothiocyanate 
TTF-1 Thyroid transcription factor 1 
TUNEL 
Terminal deoxynucleotidyltr.-mediated 
dUTP-biotin nick end labeling 
V Volt 
wt Wild type 
µg Microgram 
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